<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34663413</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy.</ArticleTitle><Pagination><StartPage>71</StartPage><MedlinePgn>71</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">71</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-021-00479-8</ELocationID><Abstract><AbstractText Label="BACKGROUND">Oxidative stress (OS) is an imbalance between oxidant and antioxidant species and, together with other numerous pathological mechanisms, leads to the degeneration and death of motor neurons (MNs) in amyotrophic lateral sclerosis (ALS).</AbstractText><AbstractText Label="MAIN BODY">Two of the main players in the molecular and cellular response to OS are NRF2, the transcription nuclear factor erythroid 2-related factor 2, and its principal negative regulator, KEAP1, Kelch-like ECH (erythroid cell-derived protein with CNC homology)-associated protein 1. Here we first provide an overview of the structural organization, regulation, and critical role of the KEAP1-NRF2 system in counteracting OS, with a focus on its alteration in ALS. We then examine several compounds capable of promoting NRF2 activity thereby inducing cytoprotective effects, and which are currently in different stages of clinical development for many pathologies, including neurodegenerative diseases.</AbstractText><AbstractText Label="CONCLUSIONS">Although challenges associated with some of these compounds remain, important advances have been made in the development of safer and more effective drugs that could actually represent a breakthrough for fatal degenerative diseases such as ALS.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bono</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5958-4499</Identifier><AffiliationInfo><Affiliation>Need Institute, Laboratory of Neurobiology for Translational Medicine, c/o Casa di Cura del Policlinico (CCP), Via Dezza 48, 20144, Milan, Italy. silvia.bono@needinstitute.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feligioni</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Need Institute, Laboratory of Neurobiology for Translational Medicine, c/o Casa di Cura del Policlinico (CCP), Via Dezza 48, 20144, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neuronal Cell Signaling, EBRI Rita Levi-Montalcini Foundation, 00161, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corbo</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0793-9830</Identifier><AffiliationInfo><Affiliation>Department of Neurorehabilitation Sciences, Casa di Cura del Policlinico (CCP), Via Dezza 48, 20144, Milan, Italy. m.corbo@ccppdezza.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C431364">KEAP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000072019">Kelch-Like ECH-Associated Protein 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495635">NFE2L2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072019" MajorTopicYN="N">Kelch-Like ECH-Associated Protein 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051267" MajorTopicYN="Y">NF-E2-Related Factor 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Antioxidant</Keyword><Keyword MajorTopicYN="N">KEAP1-NRF2</Keyword><Keyword MajorTopicYN="N">Neuroprotection</Keyword><Keyword MajorTopicYN="N">Oxidative stress</Keyword><Keyword MajorTopicYN="N">Therapeutic target</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>19</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34663413</ArticleId><ArticleId IdType="pmc">PMC8521937</ArticleId><ArticleId IdType="doi">10.1186/s13024-021-00479-8</ArticleId><ArticleId IdType="pii">10.1186/s13024-021-00479-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chiurchi&#xf9; V, Orlacchio A, Maccarrone M. Is modulation of oxidative stress an answer? The state of the art of redox therapeutic actions in neurodegenerative diseases. Oxid Med Cell Longev. 2016;2016:1&#x2013;11. doi: 10.1155/2016/7909380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/7909380</ArticleId><ArticleId IdType="pmc">PMC4736210</ArticleId><ArticleId IdType="pubmed">26881039</ArticleId></ArticleIdList></Reference><Reference><Citation>Sbodio JI, Snyder SH, Paul BD. Redox mechanisms in neurodegeneration: from disease outcomes to therapeutic opportunities. Antioxid Redox Signal. 2019;30:1450&#x2013;1499. doi: 10.1089/ars.2017.7321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2017.7321</ArticleId><ArticleId IdType="pmc">PMC6393771</ArticleId><ArticleId IdType="pubmed">29634350</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorklund G, Stejskal V, Urbina MA, Dadar M, Chirumbolo S, Mutter J. Metals and Parkinson&#x2019;s disease: mechanisms and biochemical processes. Curr Med Chem. 2018;25:2198&#x2013;2214. doi: 10.2174/0929867325666171129124616.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867325666171129124616</ArticleId><ArticleId IdType="pubmed">29189118</ArticleId></ArticleIdList></Reference><Reference><Citation>Calder&#xf3;n-Garcidue&#xf1;as L. Smoking and cerebral oxidative stress and air pollution: a dreadful equation with particulate matter involved and one more powerful reason not to smoke anything! J Alzheimers Dis. 2016;54:109&#x2013;112. doi: 10.3233/JAD-160510.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160510</ArticleId><ArticleId IdType="pubmed">27447427</ArticleId></ArticleIdList></Reference><Reference><Citation>Couillard C, Pomerleau S, Ruel G, Archer WR, Bergeron J, Couture P, et al. Associations between hypertriglyceridemia, dietary fat intake, oxidative stress, and endothelial activation in men. Nutrition. 2006;22:600&#x2013;608. doi: 10.1016/j.nut.2006.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2006.03.007</ArticleId><ArticleId IdType="pubmed">16704953</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant SS, Hung DT. Persistent bacterial infections, antibiotic tolerance, and the oxidative stress response. Virulence. 2013;4:273&#x2013;283. doi: 10.4161/viru.23987.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/viru.23987</ArticleId><ArticleId IdType="pmc">PMC3710330</ArticleId><ArticleId IdType="pubmed">23563389</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J-J, Kim Y-S, Kumar V. Heavy metal toxicity: An update of chelating therapeutic strategies. J Trace Elem Med Biol. 2019;54:226&#x2013;231. doi: 10.1016/j.jtemb.2019.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtemb.2019.05.003</ArticleId><ArticleId IdType="pubmed">31109617</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen EL, Cejvanovic V, Kjaer LK, Pedersen MT, Popik SD, Hansen LK, et al. Clarithromycin, trimethoprim, and penicillin and oxidative nucleic acid modifications in humans: randomised, controlled trials: Antibiotics and oxidative stress. Br J Clin Pharmacol. 2017;83:1643&#x2013;1653. doi: 10.1111/bcp.13261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.13261</ArticleId><ArticleId IdType="pmc">PMC5510073</ArticleId><ArticleId IdType="pubmed">28185274</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrakchi M, Liu X, Andreescu S. Oxidative stress and antibiotic resistance in bacterial pathogens: state of the art, methodologies, and future trends. Adv Exp Med Biol. 2014;806:483&#x2013;98. 10.1007/978-3-319-06068-2_23.</Citation><ArticleIdList><ArticleId IdType="pubmed">24952198</ArticleId></ArticleIdList></Reference><Reference><Citation>Massicot F, Martin C, Dutertre-Catella H, Ellouk-Achard S, Pham-Huy C, Thevenin M, et al. Modulation of energy status and cytotoxicity induced by FK506 and cyclosporin A in a renal epithelial cell line. Arch Toxicol. 1997;71:529&#x2013;531. doi: 10.1007/s002040050423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002040050423</ArticleId><ArticleId IdType="pubmed">9248632</ArticleId></ArticleIdList></Reference><Reference><Citation>Talarico C, Dattilo V, D&#x2019;Antona L, Barone A, Amodio N, Belviso S, et al. SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells. Oncotarget. 2016;7:15868&#x2013;15884. doi: 10.18632/oncotarget.7520.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.7520</ArticleId><ArticleId IdType="pmc">PMC4941283</ArticleId><ArticleId IdType="pubmed">26908461</ArticleId></ArticleIdList></Reference><Reference><Citation>Baardman J, Verberk SGS, Prange KHM, van Weeghel M, van der Velden S, Ryan DG, et al. A Defective Pentose Phosphate Pathway Reduces Inflammatory Macrophage Responses during Hypercholesterolemia. Cell Rep. 2018;25:2044&#x2013;2052.e5. doi: 10.1016/j.celrep.2018.10.092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.10.092</ArticleId><ArticleId IdType="pubmed">30463003</ArticleId></ArticleIdList></Reference><Reference><Citation>Campisi J, Kapahi P, Lithgow GJ, Melov S, Newman JC, Verdin E. From discoveries in ageing research to therapeutics for healthy ageing. Nature. 2019;571(7764):183&#x2013;92. 10.1038/s41586-019-1365-2. Epub 2019 Jul 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7205183</ArticleId><ArticleId IdType="pubmed">31292558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceriello A. Possible role of oxidative stress in the pathogenesis of hypertension. Diabetes Care. 2008;31:S181&#x2013;S184. doi: 10.2337/dc08-s245.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc08-s245</ArticleId><ArticleId IdType="pubmed">18227482</ArticleId></ArticleIdList></Reference><Reference><Citation>Dikalov S, Itani H, Richmond B, Vergeade A, Rahman SMJ, Boutaud O, Blackwell T, Massion PP, Harrison DG, Dikalova A. Tobacco smoking induces cardiovascular mitochondrial oxidative stress, promotes endothelial dysfunction, and enhances hypertension. Am J Physiol Heart Circ Physiol. 2019;316(3):H639&#x2013;H646. 10.1152/ajpheart.00595.2018. Epub 2019 Jan 4. Erratum in: Am J Physiol Heart Circ Physiol. 2019;316(4):H939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6459311</ArticleId><ArticleId IdType="pubmed">30608177</ArticleId></ArticleIdList></Reference><Reference><Citation>Dr&#xf6;ge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82:47&#x2013;95. doi: 10.1152/physrev.00018.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00018.2001</ArticleId><ArticleId IdType="pubmed">11773609</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudryavtseva AV, Krasnov GS, Dmitriev AA, Alekseev BY, Kardymon OL, Sadritdinova AF, et al. Mitochondrial dysfunction and oxidative stress in aging and cancer. Oncotarget. 2016;7:44879&#x2013;44905. doi: 10.18632/oncotarget.9821.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.9821</ArticleId><ArticleId IdType="pmc">PMC5216692</ArticleId><ArticleId IdType="pubmed">27270647</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao CY, Kennedy BK. SIRT6, oxidative stress, and aging. Cell Res. 2016;26(2):143&#x2013;4. https://doi.org/10.1038/cr.2016.8. Epub 2016 Jan 19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4746614</ArticleId><ArticleId IdType="pubmed">26780861</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyas S, Zaganjor E, Haigis MC. Mitochondria and cancer. Cell. 2016;166:555&#x2013;566. doi: 10.1016/j.cell.2016.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.07.002</ArticleId><ArticleId IdType="pmc">PMC5036969</ArticleId><ArticleId IdType="pubmed">27471965</ArticleId></ArticleIdList></Reference><Reference><Citation>Commoner B, Townsend J, Pake GE. Free radicals in biological materials. Nature. 1954;174(4432):689&#x2013;91. 10.1038/174689a0.</Citation><ArticleIdList><ArticleId IdType="pubmed">13213980</ArticleId></ArticleIdList></Reference><Reference><Citation>McCord JM. The evolution of free radicals and oxidative stress. Am J Med. 2000;108:652&#x2013;659. doi: 10.1016/S0002-9343(00)00412-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9343(00)00412-5</ArticleId><ArticleId IdType="pubmed">10856414</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham-Huy LA, He H, Pham-Huy C. Free Radicals, Antioxidants in Disease and Health. FREE Radic Antioxid. 2008;4:8.</Citation></Reference><Reference><Citation>Singh A, Kukreti R, Saso L, Kukreti S. Oxidative stress: a key modulator in neurodegenerative diseases. Molecules. 2019;24:1583. doi: 10.3390/molecules24081583.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24081583</ArticleId><ArticleId IdType="pmc">PMC6514564</ArticleId><ArticleId IdType="pubmed">31013638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartz RR, Piantadosi CA. Clinical review: oxygen as a signaling molecule. Crit Care. 2010;14:234. doi: 10.1186/cc9185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc9185</ArticleId><ArticleId IdType="pmc">PMC3219237</ArticleId><ArticleId IdType="pubmed">21062512</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedzielska E, Smaga I, Gawlik M, Moniczewski A, Stankowicz P, Pera J, et al. Oxidative stress in neurodegenerative diseases. Mol Neurobiol. 2016;53:4094&#x2013;4125. doi: 10.1007/s12035-015-9337-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9337-5</ArticleId><ArticleId IdType="pmc">PMC4937091</ArticleId><ArticleId IdType="pubmed">26198567</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreyev AY, Kushnareva YE, Starkov AA. Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc). 2005;70(2):200&#x2013;14. 10.1007/s10541-005-0102-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15807660</ArticleId></ArticleIdList></Reference><Reference><Citation>Je&#x17e;ek P, Hlavat&#xe1; L. Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and organism. Int J Biochem Cell Biol. 2005;37:2478&#x2013;2503. doi: 10.1016/j.biocel.2005.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2005.05.013</ArticleId><ArticleId IdType="pubmed">16103002</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand MD. The sites and topology of mitochondrial superoxide production. Exp Gerontol. 2010;45:466&#x2013;472. doi: 10.1016/j.exger.2010.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2010.01.003</ArticleId><ArticleId IdType="pmc">PMC2879443</ArticleId><ArticleId IdType="pubmed">20064600</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand MD, Affourtit C, Esteves TC, Green K, Lambert AJ, Miwa S, et al. Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. Free Radic Biol Med. 2004;37:755&#x2013;767. doi: 10.1016/j.freeradbiomed.2004.05.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2004.05.034</ArticleId><ArticleId IdType="pubmed">15304252</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert AJ, Brand MD. Reactive oxygen species production by mitochondria. Methods Mol Biol. 2009;554:165&#x2013;81. 10.1007/978-1-59745-521-3_11.</Citation><ArticleIdList><ArticleId IdType="pubmed">19513674</ArticleId></ArticleIdList></Reference><Reference><Citation>Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003;552:335&#x2013;344. doi: 10.1113/jphysiol.2003.049478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2003.049478</ArticleId><ArticleId IdType="pmc">PMC2343396</ArticleId><ArticleId IdType="pubmed">14561818</ArticleId></ArticleIdList></Reference><Reference><Citation>Mailloux RJ, McBride SL, Harper M-E. Unearthing the secrets of mitochondrial ROS and glutathione in bioenergetics. Trends Biochem Sci. 2013;38:592&#x2013;602. doi: 10.1016/j.tibs.2013.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2013.09.001</ArticleId><ArticleId IdType="pubmed">24120033</ArticleId></ArticleIdList></Reference><Reference><Citation>Venditti P, Di Stefano L, Di Meo S. Mitochondrial metabolism of reactive oxygen species. Mitochondrion. 2013;13:71&#x2013;82. doi: 10.1016/j.mito.2013.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2013.01.008</ArticleId><ArticleId IdType="pubmed">23376030</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicente-Gutierrez C, Bonora N, Bobo-Jimenez V, Jimenez-Blasco D, Lopez-Fabuel I, Fernandez E, et al. Astrocytic mitochondrial ROS modulate brain metabolism and mouse behaviour. Nat Metab. 2019;1:201&#x2013;211. doi: 10.1038/s42255-018-0031-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-018-0031-6</ArticleId><ArticleId IdType="pubmed">32694785</ArticleId></ArticleIdList></Reference><Reference><Citation>Giles G, Nasim M, Ali W, Jacob C. The reactive sulfur species concept: 15 years on. Antioxidants. 2017;6:38. doi: 10.3390/antiox6020038.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox6020038</ArticleId><ArticleId IdType="pmc">PMC5488018</ArticleId><ArticleId IdType="pubmed">28545257</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian K. Nitric oxide NO - biogeneration regulation and relevence to human diseases. Front Biosci. 2003;8:d264&#x2013;d278. doi: 10.2741/997.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/997</ArticleId><ArticleId IdType="pubmed">12456375</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87:315&#x2013;424. doi: 10.1152/physrev.00029.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00029.2006</ArticleId><ArticleId IdType="pmc">PMC2248324</ArticleId><ArticleId IdType="pubmed">17237348</ArticleId></ArticleIdList></Reference><Reference><Citation>Radi R. Oxygen radicals, nitric oxide, and peroxynitrite: redox pathways in molecular medicine. Proc Natl Acad Sci. 2018;115:5839&#x2013;5848. doi: 10.1073/pnas.1804932115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1804932115</ArticleId><ArticleId IdType="pmc">PMC6003358</ArticleId><ArticleId IdType="pubmed">29802228</ArticleId></ArticleIdList></Reference><Reference><Citation>Persinger RL, Poynter ME, Ckless K, Janssen-Heininger YM. Molecular mechanisms of nitrogen dioxide induced epithelial injury in the lung. Mol Cell Biochem. Springer. 2002;234:71&#x2013;80. doi: 10.1023/A:1015973530559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1015973530559</ArticleId><ArticleId IdType="pubmed">12162462</ArticleId></ArticleIdList></Reference><Reference><Citation>Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature. 1998;391:393&#x2013;397. doi: 10.1038/34923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/34923</ArticleId><ArticleId IdType="pubmed">9450756</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaut JP, Byun J, Tran HD, Lauber WM, Carroll JA, Hotchkiss RS, et al. Myeloperoxidase produces nitrating oxidants in vivo. J Clin Invest. 2002;109:1311&#x2013;1319. doi: 10.1172/JCI0215021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI0215021</ArticleId><ArticleId IdType="pmc">PMC150982</ArticleId><ArticleId IdType="pubmed">12021246</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishanina TV, Libiad M, Banerjee R. Biogenesis of reactive sulfur species for signaling by hydrogen sulfide oxidation pathways. Nat Chem Biol. 2015;11:457&#x2013;464. doi: 10.1038/nchembio.1834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1834</ArticleId><ArticleId IdType="pmc">PMC4818113</ArticleId><ArticleId IdType="pubmed">26083070</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueira TR, Barros MH, Camargo AA, Castilho RF, Ferreira JCB, Kowaltowski AJ, et al. mitochondria as a source of reactive oxygen and nitrogen species: from molecular mechanisms to human health. Antioxid Redox Signal. 2013;18:2029&#x2013;2074. doi: 10.1089/ars.2012.4729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2012.4729</ArticleId><ArticleId IdType="pubmed">23244576</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacza Z, Kozlov AV, Pankotai E, Csord&#xe1;s A, Wolf G, Redl H, et al. Mitochondria produce reactive nitrogen species via an arginine-independent pathway. Free Radic Res. 2006;40:369&#x2013;378. doi: 10.1080/10715760500539139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10715760500539139</ArticleId><ArticleId IdType="pubmed">16517501</ArticleId></ArticleIdList></Reference><Reference><Citation>Libiad M, Yadav PK, Vitvitsky V, Martinov M, Banerjee R. Organization of the human mitochondrial hydrogen sulfide oxidation pathway. J Biol Chem. 2014;289:30901&#x2013;30910. doi: 10.1074/jbc.M114.602664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.602664</ArticleId><ArticleId IdType="pmc">PMC4223297</ArticleId><ArticleId IdType="pubmed">25225291</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang EF, Scheibye-Knudsen M, Chua KF, Mattson MP, Croteau DL, Bohr VA. Nuclear DNA damage signalling to mitochondria in ageing. Nat Rev Mol Cell Biol. 2016;17:308&#x2013;321. doi: 10.1038/nrm.2016.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2016.14</ArticleId><ArticleId IdType="pmc">PMC5161407</ArticleId><ArticleId IdType="pubmed">26956196</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. 2019;20:148&#x2013;160. doi: 10.1038/s41583-019-0132-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-019-0132-6</ArticleId><ArticleId IdType="pubmed">30737462</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Domenico F, Pupo G, Giraldo E, Bad&#xec;a M-C, Monllor P, Lloret A, et al. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients. Free Radic Biol Med. 2016;91:1&#x2013;9. doi: 10.1016/j.freeradbiomed.2015.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.12.004</ArticleId><ArticleId IdType="pubmed">26675344</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60:759&#x2013;767. doi: 10.1093/jnen/60.8.759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/60.8.759</ArticleId><ArticleId IdType="pubmed">11487050</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Ratan RR. Oxidative stress and huntington&#x2019;s disease: the good, the bad, and the ugly. J Huntingt Dis. 2016;5:217&#x2013;237. doi: 10.3233/JHD-160205.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JHD-160205</ArticleId><ArticleId IdType="pmc">PMC5310831</ArticleId><ArticleId IdType="pubmed">27662334</ArticleId></ArticleIdList></Reference><Reference><Citation>Perluigi M, Poon HF, Maragos W, Pierce WM, Klein JB, Calabrese V, et al. Proteomic analysis of protein expression and oxidative modification in R6/2 transgenic mice: a model of Huntington Disease. Mol Cell Proteomics. 2005;4:1849&#x2013;1861. doi: 10.1074/mcp.M500090-MCP200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M500090-MCP200</ArticleId><ArticleId IdType="pubmed">15968004</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorolla MA, Reverter-Branchat G, Tamarit J, Ferrer I, Ros J, Cabiscol E. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med. 2008;45:667&#x2013;678. doi: 10.1016/j.freeradbiomed.2008.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2008.05.014</ArticleId><ArticleId IdType="pubmed">18588971</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA, Fowler DM, Zhang Q, Nieva J, Powers ET, Wentworth P, et al. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate &#x3b1;-synuclein fibrilization. Nat Chem Biol. 2006;2:249&#x2013;253. doi: 10.1038/nchembio782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio782</ArticleId><ArticleId IdType="pubmed">16565714</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung SY, Kishinevsky S, Mazzulli JR, Graziotto J, Mrejeru A, Mosharov EV, et al. Parkin and PINK1 patient iPSC-derived midbrain dopamine neurons exhibit mitochondrial dysfunction and &#x3b1;-Synuclein accumulation. Stem Cell Rep. 2016;7:664&#x2013;677. doi: 10.1016/j.stemcr.2016.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2016.08.012</ArticleId><ArticleId IdType="pmc">PMC5063469</ArticleId><ArticleId IdType="pubmed">27641647</ArticleId></ArticleIdList></Reference><Reference><Citation>Puspita L, Chung SY, Shim J. Oxidative stress and cellular pathologies in Parkinson&#x2019;s disease. Mol Brain. 2017;10:53. doi: 10.1186/s13041-017-0340-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-017-0340-9</ArticleId><ArticleId IdType="pmc">PMC5706368</ArticleId><ArticleId IdType="pubmed">29183391</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacman SR, Bradley WG, Moraes CT. Mitochondrial involvement in amyotrophic lateral sclerosis. Mol Neurobiol. 2006;33:19. doi: 10.1385/MN:33:2:113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/MN:33:2:113</ArticleId><ArticleId IdType="pubmed">16603792</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber SC, Mead RJ, Shaw PJ. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta. 2006;1762(11-12):1051&#x2013;67. 10.1016/j.bbadis.2006.03.008. Epub 2006 Apr 4.</Citation><ArticleIdList><ArticleId IdType="pubmed">16713195</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva EV, Ayala V, Jove M, Dalfo E, Cacabelos D, Povedano M, et al. Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain. 2007;130:3111&#x2013;3123. doi: 10.1093/brain/awm190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm190</ArticleId><ArticleId IdType="pubmed">17716997</ArticleId></ArticleIdList></Reference><Reference><Citation>Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688&#x2013;692. doi: 10.1038/s41586-019-1705-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1705-2</ArticleId><ArticleId IdType="pmc">PMC6883167</ArticleId><ArticleId IdType="pubmed">31634900</ArticleId></ArticleIdList></Reference><Reference><Citation>Olin-Sandoval V, Yu JSL, Miller-Fleming L, Alam MT, Kamrad S, Correia-Melo C, et al. Lysine harvesting is an antioxidant strategy and triggers underground polyamine metabolism. Nature. 2019;572:249&#x2013;253. doi: 10.1038/s41586-019-1442-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1442-6</ArticleId><ArticleId IdType="pmc">PMC6774798</ArticleId><ArticleId IdType="pubmed">31367038</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddi AR, Culotta VC. SOD1 integrates signals from oxygen and glucose to repress respiration. Cell. 2013;152:224&#x2013;235. doi: 10.1016/j.cell.2012.11.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.11.046</ArticleId><ArticleId IdType="pmc">PMC3552299</ArticleId><ArticleId IdType="pubmed">23332757</ArticleId></ArticleIdList></Reference><Reference><Citation>Veskovic M, Mladenovic D, Jorgacevic B, Stevanovic I, de Luka S, Radosavljevic T. Alpha-lipoic acid affects the oxidative stress in various brain structures in mice with methionine and choline deficiency. Exp Biol Med. 2015;240:418&#x2013;425. doi: 10.1177/1535370214549521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370214549521</ArticleId><ArticleId IdType="pmc">PMC4935381</ArticleId><ArticleId IdType="pubmed">25193852</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayedi A, Rashidy-Pour A, Parohan M, Zargar MS, Shab-Bidar S. Dietary antioxidants, circulating antioxidant concentrations, total antioxidant capacity, and risk of all-cause mortality: a systematic review and dose-response meta-analysis of prospective observational studies. Adv Nutr. Oxford University Press. 2018;9:701&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6247336</ArticleId><ArticleId IdType="pubmed">30239557</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn Rev. 2010;4(8):118&#x2013;26. 10.4103/0973-7847.70902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3249911</ArticleId><ArticleId IdType="pubmed">22228951</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y-Z, Yang S, Wu G. Free radicals, antioxidants, and nutrition. Nutrition. 2002;18:872&#x2013;879. doi: 10.1016/S0899-9007(02)00916-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0899-9007(02)00916-4</ArticleId><ArticleId IdType="pubmed">12361782</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado A, Rojo AI, Wells G, Hayes JD, Cousin SP, Rumsey WL, et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019;18:295&#x2013;317. doi: 10.1038/s41573-018-0008-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-018-0008-x</ArticleId><ArticleId IdType="pubmed">30610225</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DA, Johnson JA. Nrf2&#x2014;a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Biol Med. 2015;88:253&#x2013;267. doi: 10.1016/j.freeradbiomed.2015.07.147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.07.147</ArticleId><ArticleId IdType="pmc">PMC4809057</ArticleId><ArticleId IdType="pubmed">26281945</ArticleId></ArticleIdList></Reference><Reference><Citation>Paladino S, Conte A, Caggiano R, Pierantoni GM, Faraonio R. Nrf2 Pathway in Age-Related Neurological Disorders: Insights into MicroRNAs. Cell Physiol Biochem. 2018;47:1951&#x2013;1976. doi: 10.1159/000491465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000491465</ArticleId><ArticleId IdType="pubmed">29969760</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344(22):1688&#x2013;700. 10.1056/NEJM200105313442207.</Citation><ArticleIdList><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat Rev Neurol. 2017;13:96&#x2013;104. doi: 10.1038/nrneurol.2016.182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.182</ArticleId><ArticleId IdType="pubmed">27982040</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chi&#xf2; A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17:94&#x2013;102. doi: 10.1016/S1474-4422(17)30401-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245&#x2013;56. 10.1016/j.neuron.2011.09.011. Epub 2011 Sep 21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59-62. 10.1038/362059a0. Erratum in: Nature. 1993;364(6435):362.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, Groen EJN, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol (Berl). 2013;125:777&#x2013;794. doi: 10.1007/s00401-013-1125-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1125-6</ArticleId><ArticleId IdType="pmc">PMC3661910</ArticleId><ArticleId IdType="pubmed">23673820</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, van den Berg LH. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol (Berl). 2012;124:339&#x2013;352. doi: 10.1007/s00401-012-1022-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1022-4</ArticleId><ArticleId IdType="pubmed">22903397</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330(9):585&#x2013;91. 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash RP, Babu RJ, Srinivas NR. Two decades-long journey from Riluzole to Edaravone: revisiting the clinical pharmacokinetics of the only two amyotrophic lateral sclerosis therapeutics. Clin Pharmacokinet. 2018;57:1385&#x2013;1398. doi: 10.1007/s40262-018-0655-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-018-0655-4</ArticleId><ArticleId IdType="pubmed">29682695</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347(9013):1425&#x2013;31. https://doi.org/10.1016/s0140-6736(96)91680-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard A. FDA approves first deuterated drug: Nature Publishing Group; 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">28450717</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? Front Aging Neurosci. 2017;9:68. 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H. Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Rev Neurother. 2019;19:185&#x2013;193. doi: 10.1080/14737175.2019.1581610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2019.1581610</ArticleId><ArticleId IdType="pubmed">30810406</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonafede R, Mariotti R. ALS Pathogenesis and Therapeutic Approaches: The Role of Mesenchymal Stem Cells and Extracellular Vesicles. Front Cell Neurosci. 2017;11:80. 10.3389/fncel.2017.00080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5359305</ArticleId><ArticleId IdType="pubmed">28377696</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood LK, Langford SJ. Motor neuron disease: a chemical perspective. J Med Chem. 2014;57:6316&#x2013;6331. doi: 10.1021/jm5001584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm5001584</ArticleId><ArticleId IdType="pubmed">24694032</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi L, Ke Y, Luo C, Gozal D, Liu R. Depletion of reduced glutathione enhances motor neuron degeneration in vitro and in vivo. Neuroscience. 2007;144:991&#x2013;1003. doi: 10.1016/j.neuroscience.2006.09.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2006.09.064</ArticleId><ArticleId IdType="pmc">PMC1944995</ArticleId><ArticleId IdType="pubmed">17150307</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowling AC, Schulz JB, Brown RH Jr, Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem. 1993;61(6):2322&#x2013;5. 10.1111/j.1471-4159.1993.tb07478.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">8245985</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw PJ, Ince PG, Falkous G, Mantle D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol. 1995;38:691&#x2013;695. doi: 10.1002/ana.410380424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410380424</ArticleId><ArticleId IdType="pubmed">7574472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem. 1997;69:2064&#x2013;2074. doi: 10.1046/j.1471-4159.1997.69052064.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1997.69052064.x</ArticleId><ArticleId IdType="pubmed">9349552</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol. 1997;42:644&#x2013;654. doi: 10.1002/ana.410420416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410420416</ArticleId><ArticleId IdType="pubmed">9382477</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen WA, Fu W, Keller JN, Markesbery WR, Appel S, Smith RG, et al. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol. 1998;44:819&#x2013;824. doi: 10.1002/ana.410440518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410440518</ArticleId><ArticleId IdType="pubmed">9818940</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N, Nagai R, Uchida K, Horiuchi S, Yamada S, Hirano A, et al. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res. 2001;917:97&#x2013;104. doi: 10.1016/S0006-8993(01)02926-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(01)02926-2</ArticleId><ArticleId IdType="pubmed">11602233</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrante RJ, Shinobu LA, Schulz JB, Matthews RT, Thomas CE, Kowall NW, et al. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol. 1997;42:326&#x2013;334. doi: 10.1002/ana.410420309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410420309</ArticleId><ArticleId IdType="pubmed">9307254</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogdanov M, Brown RH, Matson W, Smart R, Hayden D, O&#x2019;Donnell H, et al. Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med. 2000;29:652&#x2013;658. doi: 10.1016/S0891-5849(00)00349-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0891-5849(00)00349-X</ArticleId><ArticleId IdType="pubmed">11033417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihara Y, Nobukuni K, Takata H, Hayabara T. Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation. Neurol Res. 2005;27:105&#x2013;108. doi: 10.1179/016164105X18430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/016164105X18430</ArticleId><ArticleId IdType="pubmed">15829169</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson EP, Henry YK, Henkel JS, Smith RG, Appel SH. Increased lipid peroxidation in sera of ALS patients: A potential biomarker of disease burden. Neurology. 2004;62:1758&#x2013;1765. doi: 10.1212/WNL.62.10.1758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.62.10.1758</ArticleId><ArticleId IdType="pubmed">15159474</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RG, Henry YK, Mattson MP, Appel SH. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1998;44(4):696&#x2013;9. 10.1002/ana.410440419.</Citation><ArticleIdList><ArticleId IdType="pubmed">9778272</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C. Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Neurosci Lett. 1999;260:204&#x2013;206. doi: 10.1016/S0304-3940(98)00986-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(98)00986-0</ArticleId><ArticleId IdType="pubmed">10076903</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw IC, Fitzmaurice PS, Mitchell JD, Lynch PG. Studies on cellular free radical protection mechanisms in the anterior horn from patients with amyotrophic lateral sclerosis. Neurodegeneration. 1995;4(4):391&#x2013;6. 10.1006/neur.1995.0047.</Citation><ArticleIdList><ArticleId IdType="pubmed">8846232</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita K, Yamauchi M, Shibayama K, Ando M, Honda M, Nagata Y. Decreased cytochrome c oxidase activity but unchanged superoxide dismutase and glutathione peroxidase activities in the spinal cords of patients with amyotrophic lateral sclerosis. J Neurosci Res. 1996;45:276&#x2013;281. doi: 10.1002/(SICI)1097-4547(19960801)45:3&lt;276::AID-JNR9&gt;3.0.CO;2-A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19960801)45:3&lt;276::AID-JNR9&gt;3.0.CO;2-A</ArticleId><ArticleId IdType="pubmed">8841988</ArticleId></ArticleIdList></Reference><Reference><Citation>Przedborski S, Donaldson D, Jakowec M, Kish SJ, Guttman M, Rosoklija G, et al. Brain superoxide dismutase, catalase, and glutathione peroxidase activities in amyotrophic lateral sclerosis. Ann Neurol. 1996;39:158&#x2013;165. doi: 10.1002/ana.410390204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410390204</ArticleId><ArticleId IdType="pubmed">8967746</ArticleId></ArticleIdList></Reference><Reference><Citation>Przedborski S, Donaldson DM, Murphy PL, Hirsch O, Lange D, Naini AB, et al. Blood superoxide dismutase, catalase and glutathione peroxidase activities in familial and sporadic amyotrophic lateral sclerosis. Neurodegener J Neurodegener Disord Neuroprotection Neuroregeneration. 1996;5:57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">8731383</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu GN, Kumar A, Chandra R, Puri SK, Singh RL, Kalita J, Misra UK. Oxidant-antioxidant imbalance in the erythrocytes of sporadic amyotrophic lateral sclerosis patients correlates with the progression of disease. Neurochem Int. 2008;52(6):1284&#x2013;9. 10.1016/j.neuint.2008.01.009. Epub 2008 Jan 20.</Citation><ArticleIdList><ArticleId IdType="pubmed">18308427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cova E, Bongioanni P, Cereda C, Metelli MR, Salvaneschi L, Bernuzzi S, et al. Time course of oxidant markers and antioxidant defenses in subgroups of amyotrophic lateral sclerosis patients. Neurochem Int. 2010;56:687&#x2013;693. doi: 10.1016/j.neuint.2010.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2010.02.004</ArticleId><ArticleId IdType="pubmed">20152873</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiduschat N, Mao X, Hupf J, Armstrong N, Kang G, Lange DJ, et al. Motor cortex glutathione deficit in ALS measured in vivo with the J-editing technique. Neurosci Lett. 2014;570:102&#x2013;107. doi: 10.1016/j.neulet.2014.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2014.04.020</ArticleId><ArticleId IdType="pubmed">24769125</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikawa M, Okazawa H, Tsujikawa T, Matsunaga A, Yamamura O, Mori T, et al. Increased oxidative stress is related to disease severity in the ALS motor cortex: A PET study. Neurology. 2015;84:2033&#x2013;2039. doi: 10.1212/WNL.0000000000001588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001588</ArticleId><ArticleId IdType="pubmed">25904686</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Bai Z, Qin X, Cheng Y. Aberrations in oxidative stress markers in amyotrophic lateral sclerosis: a systematic review and meta-analysis. Oxid Med Cell Longev. 2019;2019:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6590548</ArticleId><ArticleId IdType="pubmed">31281567</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrus PK, Fleck TJ, Gurney ME, Hall ED. Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem. 2002;71:2041&#x2013;2048. doi: 10.1046/j.1471-4159.1998.71052041.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1998.71052041.x</ArticleId><ArticleId IdType="pubmed">9798929</ArticleId></ArticleIdList></Reference><Reference><Citation>Casoni F, Basso M, Massignan T, Gianazza E, Cheroni C, Salmona M, et al. Protein nitration in a mouse model of familial amyotrophic lateral sclerosis: POSSIBLE MULTIFUNCTIONAL ROLE IN THE PATHOGENESIS. J Biol Chem. 2005;280:16295&#x2013;16304. doi: 10.1074/jbc.M413111200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M413111200</ArticleId><ArticleId IdType="pubmed">15699043</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Wen J, Liu J, Li L. The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J. 1999;13:2318&#x2013;2328. doi: 10.1096/fasebj.13.15.2318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fasebj.13.15.2318</ArticleId><ArticleId IdType="pubmed">10593879</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol. 2002;52:448&#x2013;457. doi: 10.1002/ana.10312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10312</ArticleId><ArticleId IdType="pubmed">12325074</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon HF, Hensley K, Thongboonkerd V, Merchant ML, Lynn BC, Pierce WM, et al. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice&#x2014;a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med. 2005;39:453&#x2013;462. doi: 10.1016/j.freeradbiomed.2005.03.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2005.03.030</ArticleId><ArticleId IdType="pubmed">16043017</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar JW, Niture SK, Jaiswal AK. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med. 2009;47:1304&#x2013;1309. doi: 10.1016/j.freeradbiomed.2009.07.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2009.07.035</ArticleId><ArticleId IdType="pmc">PMC2763938</ArticleId><ArticleId IdType="pubmed">19666107</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshmukh P, Unni S, Krishnappa G, Padmanabhan B. The Keap1&#x2013;Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017;9:41&#x2013;56. doi: 10.1007/s12551-016-0244-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12551-016-0244-4</ArticleId><ArticleId IdType="pmc">PMC5425799</ArticleId><ArticleId IdType="pubmed">28510041</ArticleId></ArticleIdList></Reference><Reference><Citation>Canning P, Cooper CDO, Krojer T, Murray JW, Pike ACW, Chaikuad A, et al. Structural basis for Cul3 protein assembly with the BTB-Kelch Family of E3 ubiquitin ligases. J Biol Chem. 2013;288:7803&#x2013;7814. doi: 10.1074/jbc.M112.437996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.437996</ArticleId><ArticleId IdType="pmc">PMC3597819</ArticleId><ArticleId IdType="pubmed">23349464</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhanoa BS, Cogliati T, Satish AG, Bruford EA, Friedman JS. Update on the Kelch-like (KLHL) gene family. Hum Genomics. 2013;7:13. doi: 10.1186/1479-7364-7-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-7364-7-13</ArticleId><ArticleId IdType="pmc">PMC3658946</ArticleId><ArticleId IdType="pubmed">23676014</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999;13:76&#x2013;86. doi: 10.1101/gad.13.1.76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.13.1.76</ArticleId><ArticleId IdType="pmc">PMC316370</ArticleId><ArticleId IdType="pubmed">9887101</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang DD, Lo S-C, Cross JV, Templeton DJ, Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol. 2004;24:10941&#x2013;10953. doi: 10.1128/MCB.24.24.10941-10953.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.24.24.10941-10953.2004</ArticleId><ArticleId IdType="pmc">PMC533977</ArticleId><ArticleId IdType="pubmed">15572695</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi A, Kang M-I, Okawa H, Ohtsuji M, Zenke Y, Chiba T, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-Based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol. 2004;24:7130&#x2013;7139. doi: 10.1128/MCB.24.16.7130-7139.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.24.16.7130-7139.2004</ArticleId><ArticleId IdType="pmc">PMC479737</ArticleId><ArticleId IdType="pubmed">15282312</ArticleId></ArticleIdList></Reference><Reference><Citation>Canning P, Sorrell FJ, Bullock AN. Structural basis of Keap1 interactions with Nrf2. Free Radic Biol Med. 2015;88:101&#x2013;107. doi: 10.1016/j.freeradbiomed.2015.05.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.05.034</ArticleId><ArticleId IdType="pmc">PMC4668279</ArticleId><ArticleId IdType="pubmed">26057936</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013;27:2179&#x2013;2191. doi: 10.1101/gad.225680.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.225680.113</ArticleId><ArticleId IdType="pmc">PMC3814639</ArticleId><ArticleId IdType="pubmed">24142871</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleasby A, Yon J, Day PJ, Richardson C, Tickle IJ, Williams PA, et al. Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO. Xu E, editor. PLoS ONE. 2014;9:e98896. doi: 10.1371/journal.pone.0098896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0098896</ArticleId><ArticleId IdType="pmc">PMC4045772</ArticleId><ArticleId IdType="pubmed">24896564</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo S-C, Li X, Henzl MT, Beamer LJ, Hannink M. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. EMBO J. 2006;25:3605&#x2013;3617. doi: 10.1038/sj.emboj.7601243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7601243</ArticleId><ArticleId IdType="pmc">PMC1538563</ArticleId><ArticleId IdType="pubmed">16888629</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipper LM, Mulcahy RT. The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J Biol Chem. 2002;277:36544&#x2013;36552. doi: 10.1074/jbc.M206530200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M206530200</ArticleId><ArticleId IdType="pubmed">12145307</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogura T, Tong KI, Mio K, Maruyama Y, Kurokawa H, Sato C, et al. Keap1 is a forked-stem dimer structure with two large spheres enclosing the intervening, double glycine repeat, and C-terminal domains. Proc Natl Acad Sci. 2010;107:2842&#x2013;2847. doi: 10.1073/pnas.0914036107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0914036107</ArticleId><ArticleId IdType="pmc">PMC2840362</ArticleId><ArticleId IdType="pubmed">20133743</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukutomi T, Takagi K, Mizushima T, Ohuchi N, Yamamoto M. Kinetic, thermodynamic, and structural characterizations of the association between Nrf2-DLGex Degron and Keap1. Mol Cell Biol. 2014;34:832&#x2013;846. doi: 10.1128/MCB.01191-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.01191-13</ArticleId><ArticleId IdType="pmc">PMC4023822</ArticleId><ArticleId IdType="pubmed">24366543</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong KI, Padmanabhan B, Kobayashi A, Shang C, Hirotsu Y, Yokoyama S, et al. Different electrostatic potentials define ETGE and DLG Motifs as hinge and latch in oxidative stress response. Mol Cell Biol. 2007;27:7511&#x2013;7521. doi: 10.1128/MCB.00753-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00753-07</ArticleId><ArticleId IdType="pmc">PMC2169061</ArticleId><ArticleId IdType="pubmed">17785452</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, Yamamoto M. Keap1 Recruits Neh2 through Binding to ETGE and DLG Motifs: Characterization of the Two-Site Molecular Recognition Model. Mol Cell Biol. 2006;26:2887&#x2013;2900. doi: 10.1128/MCB.26.8.2887-2900.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.26.8.2887-2900.2006</ArticleId><ArticleId IdType="pmc">PMC1446969</ArticleId><ArticleId IdType="pubmed">16581765</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Jiang T, Wang H, Tao S, Lau A, Fang D, et al. Does Nrf2 contribute to p53-mediated control of cell survival and death? Antioxid Redox Signal. 2012;17:1670&#x2013;1675. doi: 10.1089/ars.2012.4674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2012.4674</ArticleId><ArticleId IdType="pmc">PMC3474188</ArticleId><ArticleId IdType="pubmed">22559194</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Z, Wirth A-K, Chen D, Wruck CJ, Rauh M, Buchfelder M, et al. Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis. 2017;6:e371&#x2013;e371. doi: 10.1038/oncsis.2017.65.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/oncsis.2017.65</ArticleId><ArticleId IdType="pmc">PMC5608917</ArticleId><ArticleId IdType="pubmed">28805788</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi EH, Suzuki T, Funayama R, Nagashima T, Hayashi M, Sekine H, et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun. 2016;7:11624. doi: 10.1038/ncomms11624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11624</ArticleId><ArticleId IdType="pmc">PMC4879264</ArticleId><ArticleId IdType="pubmed">27211851</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 2012;22:66&#x2013;79. doi: 10.1016/j.ccr.2012.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2012.05.016</ArticleId><ArticleId IdType="pubmed">22789539</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy NM, Kleeberger SR, Bream JH, Fallon PG, Kensler TW, Yamamoto M, et al. Genetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signaling. Oncogene. 2008;27:5821&#x2013;5832. doi: 10.1038/onc.2008.188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2008.188</ArticleId><ArticleId IdType="pmc">PMC2646365</ArticleId><ArticleId IdType="pubmed">18542053</ArticleId></ArticleIdList></Reference><Reference><Citation>Thimmulappa RK. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest. 2006;116:984&#x2013;995. doi: 10.1172/JCI25790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI25790</ArticleId><ArticleId IdType="pmc">PMC1421348</ArticleId><ArticleId IdType="pubmed">16585964</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q. Role of Nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401&#x2013;426. doi: 10.1146/annurev-pharmtox-011112-140320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-011112-140320</ArticleId><ArticleId IdType="pmc">PMC4680839</ArticleId><ArticleId IdType="pubmed">23294312</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J-M, Calkins MJ, Chan K, Kan YW, Johnson JA. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem. 2003;278:12029&#x2013;12038. doi: 10.1074/jbc.M211558200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M211558200</ArticleId><ArticleId IdType="pubmed">12556532</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh JH, Shenvi SV, Dixon BM, Liu H, Jaiswal AK, Liu R-M, et al. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci. 2004;101:3381&#x2013;3386. doi: 10.1073/pnas.0400282101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0400282101</ArticleId><ArticleId IdType="pmc">PMC373470</ArticleId><ArticleId IdType="pubmed">14985508</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K, Lu R, Chang JC, Kan YW. NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proc Natl Acad Sci. 1996;93:13943&#x2013;13948. doi: 10.1073/pnas.93.24.13943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.24.13943</ArticleId><ArticleId IdType="pmc">PMC19474</ArticleId><ArticleId IdType="pubmed">8943040</ArticleId></ArticleIdList></Reference><Reference><Citation>Moi P, Chan K, Asunis I, Cao A, Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci. National Acad Sciences; 1994;91:9926&#x2013;9930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44930</ArticleId><ArticleId IdType="pubmed">7937919</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinkova-Kostova AT, Kostov RV, Kazantsev AG. The role of Nrf2 signaling in counteracting neurodegenerative diseases. FEBS J. 2018;285:3576&#x2013;3590. doi: 10.1111/febs.14379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.14379</ArticleId><ArticleId IdType="pmc">PMC6221096</ArticleId><ArticleId IdType="pubmed">29323772</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonelli C, Chio IIC, Tuveson DA. Transcriptional regulation by Nrf2. Antioxid Redox Signal. 2018;29:1727&#x2013;1745. doi: 10.1089/ars.2017.7342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2017.7342</ArticleId><ArticleId IdType="pmc">PMC6208165</ArticleId><ArticleId IdType="pubmed">28899199</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoh Y, Iida K, Kang M-I, Kobayashi A, Mizukami M, Tong KI, et al. Evolutionary conserved N-terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the protein by proteasome. Arch Biochem Biophys. 2005;433:342&#x2013;350. doi: 10.1016/j.abb.2004.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2004.10.012</ArticleId><ArticleId IdType="pubmed">15581590</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a &#x201c;Tethering&#x201d; mechanism: a TWO-SITE INTERACTION MODEL FOR THE Nrf2-Keap1 COMPLEXA TWO-SITE INTERACTION MODEL FOR THE Nrf2-Keap1 COMPLEX. J Biol Chem. 2006;281:24756&#x2013;68. J Biol Chem. 2006;281:24756&#x2013;24768. doi: 10.1074/jbc.M601119200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M601119200</ArticleId><ArticleId IdType="pubmed">16790436</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 Degron and the Redox-insensitive Neh6 Degron. J Biol Chem. 2004;279:31556&#x2013;31567. doi: 10.1074/jbc.M403061200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M403061200</ArticleId><ArticleId IdType="pubmed">15143058</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoh Y, Itoh K, Yoshida E, Miyagishi M, Fukamizu A, Yamamoto M. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription: Synergistic activation of Nrf2 by CBP. Genes Cells. 2001;6:857&#x2013;868. doi: 10.1046/j.1365-2443.2001.00469.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2443.2001.00469.x</ArticleId><ArticleId IdType="pubmed">11683914</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu M, Fahl WE. Functional characterization of transcription regulators that interact with the electrophile response element. Biochem Biophys Res Commun. 2001;289:212&#x2013;219. doi: 10.1006/bbrc.2001.5944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.2001.5944</ArticleId><ArticleId IdType="pubmed">11708801</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Liu K, Geng M, Gao P, Wu X, Hai Y, et al. RXR inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 Domain of NRF2. Cancer Res. 2013;73:3097&#x2013;3108. doi: 10.1158/0008-5472.CAN-12-3386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-12-3386</ArticleId><ArticleId IdType="pubmed">23612120</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhry S, Zhang Y, McMahon M, Sutherland C, Cuadrado A, Hayes JD. Nrf2 is controlled by two distinct &#x3b2;-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene. 2013;32:3765&#x2013;3781. doi: 10.1038/onc.2012.388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2012.388</ArticleId><ArticleId IdType="pmc">PMC3522573</ArticleId><ArticleId IdType="pubmed">22964642</ArticleId></ArticleIdList></Reference><Reference><Citation>Rada P, Rojo AI, Evrard-Todeschi N, Innamorato NG, Cotte A, Jaworski T, et al. Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/ -TrCP axis. Mol Cell Biol. 2012;32:3486&#x2013;3499. doi: 10.1128/MCB.00180-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00180-12</ArticleId><ArticleId IdType="pmc">PMC3422007</ArticleId><ArticleId IdType="pubmed">22751928</ArticleId></ArticleIdList></Reference><Reference><Citation>Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, Cuadrado A. SCF/ -TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol. 2011;31:1121&#x2013;1133. doi: 10.1128/MCB.01204-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.01204-10</ArticleId><ArticleId IdType="pmc">PMC3067901</ArticleId><ArticleId IdType="pubmed">21245377</ArticleId></ArticleIdList></Reference><Reference><Citation>Motohashi H, Katsuoka F, Engel JD, Yamamoto M. Small Maf proteins serve as transcriptional cofactors for keratinocyte differentiation in the Keap1-Nrf2 regulatory pathway. Proc Natl Acad Sci. 2004;101:6379&#x2013;6384. doi: 10.1073/pnas.0305902101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0305902101</ArticleId><ArticleId IdType="pmc">PMC404053</ArticleId><ArticleId IdType="pubmed">15087497</ArticleId></ArticleIdList></Reference><Reference><Citation>Nioi P, Nguyen T, Sherratt PJ, Pickett CB. The carboxy-terminal Neh3 Domain of Nrf2 Is required for transcriptional activation. Mol Cell Biol. 2005;25:10895&#x2013;10906. doi: 10.1128/MCB.25.24.10895-10906.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.25.24.10895-10906.2005</ArticleId><ArticleId IdType="pmc">PMC1316965</ArticleId><ArticleId IdType="pubmed">16314513</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao S, Liu P, Luo G, Rojo dela Vega M, Chen H, Wu T, et al. p97 Negatively Regulates NRF2 by Extracting Ubiquitylated NRF2 from the KEAP1-CUL3 E3 Complex. Mol Cell Biol. 2017;37:e00660-16. doi: 10.1128/MCB.00660-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00660-16</ArticleId><ArticleId IdType="pmc">PMC5376629</ArticleId><ArticleId IdType="pubmed">28115426</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-Based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol. 2004;24:8477&#x2013;8486. doi: 10.1128/MCB.24.19.8477-8486.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.24.19.8477-8486.2004</ArticleId><ArticleId IdType="pmc">PMC516753</ArticleId><ArticleId IdType="pubmed">15367669</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva-Islas CA, Maldonado PD. Canonical and non-canonical mechanisms of Nrf2 activation. Pharmacol Res. 2018;134:92&#x2013;99. doi: 10.1016/j.phrs.2018.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2018.06.013</ArticleId><ArticleId IdType="pubmed">29913224</ArticleId></ArticleIdList></Reference><Reference><Citation>Baird L, Lleres D, Swift S, Dinkova-Kostova AT. Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex. Proc Natl Acad Sci. 2013;110:15259&#x2013;15264. doi: 10.1073/pnas.1305687110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1305687110</ArticleId><ArticleId IdType="pmc">PMC3780858</ArticleId><ArticleId IdType="pubmed">23986495</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang DD, Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003;23:8137&#x2013;8151. doi: 10.1128/MCB.23.22.8137-8151.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.23.22.8137-8151.2003</ArticleId><ArticleId IdType="pmc">PMC262403</ArticleId><ArticleId IdType="pubmed">14585973</ArticleId></ArticleIdList></Reference><Reference><Citation>Harder B, Jiang T, Wu T, Tao S, de la Vega MR, Tian W, et al. Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease intervention. Biochem Soc Trans. 2015;43:680&#x2013;686. doi: 10.1042/BST20150020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20150020</ArticleId><ArticleId IdType="pmc">PMC4613518</ArticleId><ArticleId IdType="pubmed">26551712</ArticleId></ArticleIdList></Reference><Reference><Citation>Theodore M, Kawai Y, Yang J, Kleshchenko Y, Reddy SP, Villalta F, et al. Multiple nuclear localization signals function in the nuclear import of the transcription factor Nrf2. J Biol Chem. 2008;283:8984&#x2013;8994. doi: 10.1074/jbc.M709040200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M709040200</ArticleId><ArticleId IdType="pmc">PMC2276363</ArticleId><ArticleId IdType="pubmed">18238777</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh K, Wakabayashi N, Katoh Y, Ishii T, O&#x2019;Connor T, Yamamoto M. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells. Wiley Online Library. 2003;8:379&#x2013;391. doi: 10.1046/j.1365-2443.2003.00640.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2443.2003.00640.x</ArticleId><ArticleId IdType="pubmed">12653965</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirotsu Y, Katsuoka F, Funayama R, Nagashima T, Nishida Y, Nakayama K, et al. Nrf2&#x2013;MafG heterodimers contribute globally to antioxidant and metabolic networks. Nucleic Acids Res. 2012;40:10228&#x2013;10239. doi: 10.1093/nar/gks827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks827</ArticleId><ArticleId IdType="pmc">PMC3488259</ArticleId><ArticleId IdType="pubmed">22965115</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan L, Johnson JA. Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases. Biochim Biophys Acta BBA - Mol Basis Dis. 1842;2014:1208&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">24382478</ArticleId></ArticleIdList></Reference><Reference><Citation>Pajares M, Jim&#xe9;nez-Moreno N, Garc&#xed;a-Yag&#xfc;e &#xc1;J, Escoll M, de Ceballos ML, Van Leuven F, et al. Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes. Autophagy. 2016;12:1902&#x2013;1916. doi: 10.1080/15548627.2016.1208889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2016.1208889</ArticleId><ArticleId IdType="pmc">PMC5079676</ArticleId><ArticleId IdType="pubmed">27427974</ArticleId></ArticleIdList></Reference><Reference><Citation>Uruno A, Yagishita Y, Katsuoka F, Kitajima Y, Nunomiya A, Nagatomi R, et al. Nrf2-mediated regulation of skeletal muscle glycogen metabolism. Mol Cell Biol. 2016;36:1655&#x2013;1672. doi: 10.1128/MCB.01095-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.01095-15</ArticleId><ArticleId IdType="pmc">PMC4959318</ArticleId><ArticleId IdType="pubmed">27044864</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Yu S-W, Kong A-NT. Nrf2 possesses a redox-sensitive nuclear exporting signal in the Neh5 transactivation domain. J Biol Chem. 2006;281:27251&#x2013;27263. doi: 10.1074/jbc.M602746200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M602746200</ArticleId><ArticleId IdType="pubmed">16790425</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z, Wu T, Zhao F, Lau A, Birch CM, Zhang DD. KPNA6 (Importin 7)-mediated nuclear import of Keap1 represses the Nrf2-dependent antioxidant response. Mol Cell Biol. 2011;31:1800&#x2013;1811. doi: 10.1128/MCB.05036-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.05036-11</ArticleId><ArticleId IdType="pmc">PMC3133232</ArticleId><ArticleId IdType="pubmed">21383067</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z, Zhang S, Chan JY, Zhang DD. Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2. Mol Cell Biol. 2007;27:6334&#x2013;6349. doi: 10.1128/MCB.00630-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00630-07</ArticleId><ArticleId IdType="pmc">PMC2099624</ArticleId><ArticleId IdType="pubmed">17636022</ArticleId></ArticleIdList></Reference><Reference><Citation>Tebay LE, Robertson H, Durant ST, Vitale SR, Penning TM, Dinkova-Kostova AT, et al. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic Biol Med. 2015;88:108&#x2013;146. doi: 10.1016/j.freeradbiomed.2015.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.06.021</ArticleId><ArticleId IdType="pmc">PMC4659505</ArticleId><ArticleId IdType="pubmed">26122708</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri S, K&#xf6;rner S, Kiaei M. Nrf2/ARE signaling pathway: key mediator in oxidative stress and potential therapeutic target in ALS. Neurol Res Int. 2012;2012:1&#x2013;7. doi: 10.1155/2012/878030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/878030</ArticleId><ArticleId IdType="pmc">PMC3461296</ArticleId><ArticleId IdType="pubmed">23050144</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang HJ, Hong YB, Kim HJ, Rodriguez OC, Nath RG, Tilli EM, et al. Detoxification: a novel function of BRCA1 in tumor suppression? Toxicol Sci. 2011;122:26&#x2013;37. doi: 10.1093/toxsci/kfr089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/toxsci/kfr089</ArticleId><ArticleId IdType="pmc">PMC3143468</ArticleId><ArticleId IdType="pubmed">21507987</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao W, Hu L, Scrivens PJ, Batist G. Transcriptional regulation of nf-e2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: DIRECT CROSS-TALK BETWEEN PHASE I AND II DRUG-METABOLIZING ENZYMES. J Biol Chem. 2005;280:20340&#x2013;20348. doi: 10.1074/jbc.M412081200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M412081200</ArticleId><ArticleId IdType="pubmed">15790560</ArticleId></ArticleIdList></Reference><Reference><Citation>Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM, MacEwan DJ. The high Nrf2 expression in human acute myeloid leukemia is driven by NF-&#x3ba;B and underlies its chemo-resistance. Blood. 2012;120:5188&#x2013;5198. doi: 10.1182/blood-2012-04-422121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-04-422121</ArticleId><ArticleId IdType="pubmed">23077289</ArticleId></ArticleIdList></Reference><Reference><Citation>Rushworth SA, MacEwan DJ, O&#x2019;Connell MA. Lipopolysaccharide-induced expression of NAD(P)H:Quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive inflammatory responses in human monocytes. J Immunol. 2008;181:6730&#x2013;6737. doi: 10.4049/jimmunol.181.10.6730.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.10.6730</ArticleId><ArticleId IdType="pmc">PMC2923058</ArticleId><ArticleId IdType="pubmed">18981090</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Li J, Yang X, Sun H, Gao S, Zhu H, et al. Nrf2 is associated with the regulation of basal transcription activity of the BRCA1 gene. Acta Biochim Biophys Sin. 2013;45:179&#x2013;187. doi: 10.1093/abbs/gmt001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/abbs/gmt001</ArticleId><ArticleId IdType="pubmed">23353771</ArticleId></ArticleIdList></Reference><Reference><Citation>Koundouros N, Poulogiannis G. Phosphoinositide 3-Kinase/Akt signaling and redox metabolism in cancer. Front Oncol. 2018;8:160. doi: 10.3389/fonc.2018.00160.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2018.00160</ArticleId><ArticleId IdType="pmc">PMC5968394</ArticleId><ArticleId IdType="pubmed">29868481</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi N, Skoko JJ, Chartoumpekis DV, Kimura S, Slocum SL, Noda K, et al. Notch-Nrf2 Axis: regulation of Nrf2 gene expression and cytoprotection by Notch signaling. Mol Cell Biol. 2014;34:653&#x2013;663. doi: 10.1128/MCB.01408-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.01408-13</ArticleId><ArticleId IdType="pmc">PMC3911489</ArticleId><ArticleId IdType="pubmed">24298019</ArticleId></ArticleIdList></Reference><Reference><Citation>Eades G, Yang M, Yao Y, Zhang Y, Zhou Q. miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. J Biol Chem. 2011;286:40725&#x2013;40733. doi: 10.1074/jbc.M111.275495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.275495</ArticleId><ArticleId IdType="pmc">PMC3220489</ArticleId><ArticleId IdType="pubmed">21926171</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281&#x2013;97. 10.1016/s0092-8674(04)00045-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744438</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008;19:92&#x2013;105. doi: 10.1101/gr.082701.108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.082701.108</ArticleId><ArticleId IdType="pmc">PMC2612969</ArticleId><ArticleId IdType="pubmed">18955434</ArticleId></ArticleIdList></Reference><Reference><Citation>Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009;11:228&#x2013;234. doi: 10.1038/ncb0309-228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb0309-228</ArticleId><ArticleId IdType="pubmed">19255566</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabaria S, Choi DC, Chaudhuri AD, Jain MR, Li H, Junn E. MicroRNA-7 activates Nrf2 pathway by targeting Keap1 expression. Free Radic Biol Med. 2015;89:548&#x2013;556. doi: 10.1016/j.freeradbiomed.2015.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.09.010</ArticleId><ArticleId IdType="pmc">PMC4684759</ArticleId><ArticleId IdType="pubmed">26453926</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein LD, Lee J, Gnad F, Klijn C, Schaub A, Reeder J, et al. Recurrent loss of NFE2L2 Exon 2 is a mechanism for Nrf2 pathway activation in human cancers. Cell Rep. 2016;16:2605&#x2013;2617. doi: 10.1016/j.celrep.2016.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.08.010</ArticleId><ArticleId IdType="pubmed">27568559</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryan HK, Olayanju A, Goldring CE, Park BK. The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol. 2013;85:705&#x2013;717. doi: 10.1016/j.bcp.2012.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2012.11.016</ArticleId><ArticleId IdType="pubmed">23219527</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Sun Z, Wang X-J, Jiang T, Huang Z, Fang D, et al. Direct interaction between Nrf2 and p21Cip1/WAF1 upregulates the Nrf2-mediated antioxidant response. Mol Cell. 2009;34:663&#x2013;673. doi: 10.1016/j.molcel.2009.04.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2009.04.029</ArticleId><ArticleId IdType="pmc">PMC2714804</ArticleId><ArticleId IdType="pubmed">19560419</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorrini C, Baniasadi PS, Harris IS, Silvester J, Inoue S, Snow B, et al. BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med. 2013;210:1529&#x2013;1544. doi: 10.1084/jem.20121337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20121337</ArticleId><ArticleId IdType="pmc">PMC3727320</ArticleId><ArticleId IdType="pubmed">23857982</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo S-C, Hannink M. PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to mitochondria. Exp Cell Res. 2008;314:1789&#x2013;1803. doi: 10.1016/j.yexcr.2008.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2008.02.014</ArticleId><ArticleId IdType="pmc">PMC2409987</ArticleId><ArticleId IdType="pubmed">18387606</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo S-C, Hannink M. PGAM5, a Bcl-XL-interacting Protein, Is a Novel Substrate for the Redox-regulated Keap1-dependent Ubiquitin Ligase Complex. J Biol Chem. American Society for Biochemistry and Molecular Biology. 2006;281:37893&#x2013;37903.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046835</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Cai H, Wu T, Sobhian B, Huo Y, Alcivar A, et al. PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. Mol Cell Biol. 2012;32:1506&#x2013;1517. doi: 10.1128/MCB.06271-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.06271-11</ArticleId><ArticleId IdType="pmc">PMC3318596</ArticleId><ArticleId IdType="pubmed">22331464</ArticleId></ArticleIdList></Reference><Reference><Citation>Hast BE, Goldfarb D, Mulvaney KM, Hast MA, Siesser PF, Yan F, et al. Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination. Cancer Res. 2013;73:2199&#x2013;2210. doi: 10.1158/0008-5472.CAN-12-4400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-12-4400</ArticleId><ArticleId IdType="pmc">PMC3618590</ArticleId><ArticleId IdType="pubmed">23382044</ArticleId></ArticleIdList></Reference><Reference><Citation>Prajapati SC, Chauhan SS. Dipeptidyl peptidase III: a multifaceted oligopeptide N-end cutter: Dipeptidyl peptidase III. FEBS J. 2011;278:3256&#x2013;3276. doi: 10.1111/j.1742-4658.2011.08275.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2011.08275.x</ArticleId><ArticleId IdType="pubmed">21794094</ArticleId></ArticleIdList></Reference><Reference><Citation>Karapetian RN, Evstafieva AG, Abaeva IS, Chichkova NV, Filonov GS, Rubtsov YP, et al. Nuclear oncoprotein prothymosin &#x2423; is a partner of Keap1: implications for expression of oxidative stress-protecting genes. MOL CELL BIOL. 2005;25:11. doi: 10.1128/MCB.25.3.1089-1099.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.25.3.1089-1099.2005</ArticleId><ArticleId IdType="pmc">PMC544000</ArticleId><ArticleId IdType="pubmed">15657435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiemstra S, Niemeijer M, Koedoot E, Wink S, Klip JE, Vlasveld M, et al. Comprehensive landscape of Nrf2 and p53 pathway activation dynamics by oxidative stress and DNA damage. Chem Res Toxicol. 2017;30:923&#x2013;933. doi: 10.1021/acs.chemrestox.6b00322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrestox.6b00322</ArticleId><ArticleId IdType="pubmed">27982581</ArticleId></ArticleIdList></Reference><Reference><Citation>Padmanabhan B, Nakamura Y, Yokoyama S. Structural analysis of the complex of Keap1 with a prothymosin &#x3b1; peptide. Acta Crystallograph Sect F Struct Biol Cryst Commun. 2008;64:233&#x2013;238. doi: 10.1107/S1744309108004995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S1744309108004995</ArticleId><ArticleId IdType="pmc">PMC2374262</ArticleId><ArticleId IdType="pubmed">18391415</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon M, Lamont DJ, Beattie KA, Hayes JD. Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc Natl Acad Sci. 2010;107:18838&#x2013;18843. doi: 10.1073/pnas.1007387107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1007387107</ArticleId><ArticleId IdType="pmc">PMC2973898</ArticleId><ArticleId IdType="pubmed">20956331</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol. 2010;12:213&#x2013;223. doi: 10.1038/ncb2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb2021</ArticleId><ArticleId IdType="pubmed">20173742</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuragi Y, Ichimura Y, Komatsu M. Regulation of the Keap1&#x2013;Nrf2 pathway by p62/SQSTM1. Curr Opin Toxicol. 2016;1:54&#x2013;61. doi: 10.1016/j.cotox.2016.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cotox.2016.09.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichimura Y, Waguri S, Sou Y, Kageyama S, Hasegawa J, Ishimura R, et al. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell. 2013;51:618&#x2013;631. doi: 10.1016/j.molcel.2013.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2013.08.003</ArticleId><ArticleId IdType="pubmed">24011591</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain A, Lamark T, Sj&#xf8;ttem E, Larsen KB, Awuh JA, &#xd8;vervatn A, et al. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J Biol Chem. ASBMB. 2010;285:22576&#x2013;22591. doi: 10.1074/jbc.M110.118976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.118976</ArticleId><ArticleId IdType="pmc">PMC2903417</ArticleId><ArticleId IdType="pubmed">20452972</ArticleId></ArticleIdList></Reference><Reference><Citation>Blank V, Andrews NC. The Maf transcription factors: regulators of differentiation. Trends Biochem Sci. 1997;22(11):437&#x2013;41. 10.1016/s0968-0004(97)01105-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9397686</ArticleId></ArticleIdList></Reference><Reference><Citation>Motohashi H, O&#x2019;Connor T, Katsuoka F, Engel JD, Yamamoto M. Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. Gene. 2002;294:1&#x2013;12. doi: 10.1016/S0378-1119(02)00788-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0378-1119(02)00788-6</ArticleId><ArticleId IdType="pubmed">12234662</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Yu S, Liu T, Kim J-H, Blank V, Li H, et al. Heterodimerization with small Maf proteins enhances nuclear retention of Nrf2 via masking the NESzip motif. Biochim Biophys Acta BBA - Mol Cell Res. 1783;2008:1847&#x2013;1856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570698</ArticleId><ArticleId IdType="pubmed">18585411</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H-C, Nguyen T, Pickett CB. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem. 2002;277:42769&#x2013;42774. doi: 10.1074/jbc.M206911200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M206911200</ArticleId><ArticleId IdType="pubmed">12198130</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg SF. Mechanisms for redox-regulation of protein kinase C. Front Pharmacol. 2015;6:128. 10.3389/fphar.2015.00128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477140</ArticleId><ArticleId IdType="pubmed">26157389</ArticleId></ArticleIdList></Reference><Reference><Citation>Litchfield DW. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J. 2003;369:1&#x2013;15. doi: 10.1042/bj20021469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj20021469</ArticleId><ArticleId IdType="pmc">PMC1223072</ArticleId><ArticleId IdType="pubmed">12396231</ArticleId></ArticleIdList></Reference><Reference><Citation>Pi J, Bai Y, Reece JM, Williams J, Liu D, Freeman ML, et al. Molecular mechanism of human Nrf2 activation and degradation: Role of sequential phosphorylation by protein kinase CK2. Free Radic Biol Med. 2007;42:1797&#x2013;1806. doi: 10.1016/j.freeradbiomed.2007.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2007.03.001</ArticleId><ArticleId IdType="pmc">PMC1950666</ArticleId><ArticleId IdType="pubmed">17512459</ArticleId></ArticleIdList></Reference><Reference><Citation>Apopa PL, He X, Ma Q. Phosphorylation of Nrf2 in the transcription activation domain by casein kinase 2 (CK2) is critical for the nuclear translocation and transcription activation function of Nrf2 in IMR-32 neuroblastoma cells. J Biochem Mol Toxicol. 2008;22:63&#x2013;76. doi: 10.1002/jbt.20212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbt.20212</ArticleId><ArticleId IdType="pubmed">18273910</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, Diehl JA. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol. 2003;23:7198&#x2013;7209. doi: 10.1128/MCB.23.20.7198-7209.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.23.20.7198-7209.2003</ArticleId><ArticleId IdType="pmc">PMC230321</ArticleId><ArticleId IdType="pubmed">14517290</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X, Xu C, Pan Z, Keum Y-S, Kim J-H, Shen G, et al. Butylated hydroxyanisole regulates ARE-mediated gene expression via Nrf2 coupled with ERK and JNK signaling pathway in HepG2 cells: ACTIVATION OF Nrf2-ARE SIGNALING BY BHA AND MAPK. Mol Carcinog. 2006;45:841&#x2013;850. doi: 10.1002/mc.20234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mc.20234</ArticleId><ArticleId IdType="pubmed">16739127</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z, Huang Z, Zhang DD. Phosphorylation of Nrf2 at Multiple Sites by MAP Kinases Has a Limited Contribution in Modulating the Nrf2-Dependent Antioxidant Response. Morty RE, editor. PLoS ONE. 2009;4:e6588. doi: 10.1371/journal.pone.0006588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0006588</ArticleId><ArticleId IdType="pmc">PMC2719090</ArticleId><ArticleId IdType="pubmed">19668370</ArticleId></ArticleIdList></Reference><Reference><Citation>Lage R, Di&#xe9;guez C, Vidal-Puig A, L&#xf3;pez M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med. 2008;14:539&#x2013;549. doi: 10.1016/j.molmed.2008.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2008.09.007</ArticleId><ArticleId IdType="pubmed">18977694</ArticleId></ArticleIdList></Reference><Reference><Citation>Joo MS, Kim WD, Lee KY, Kim JH, Koo JH, Kim SG. AMPK facilitates nuclear accumulation of Nrf2 by phosphorylating at serine 550. Mol Cell Biol. 2016;36:1931&#x2013;1942. doi: 10.1128/MCB.00118-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00118-16</ArticleId><ArticleId IdType="pmc">PMC4936058</ArticleId><ArticleId IdType="pubmed">27161318</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar M, Rojo AI, Velasco D, de Sagarra RM, Cuadrado A. Glycogen synthase kinase-3&#x3b2; Inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J Biol Chem. 2006;281:14841&#x2013;14851. doi: 10.1074/jbc.M513737200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M513737200</ArticleId><ArticleId IdType="pubmed">16551619</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z, Chin YE, Zhang DD. Acetylation of Nrf2 by p300/CBP AUGMENTS PROMOTER-SPECIFIC DNA binding of Nrf2 during the antioxidant response. Mol Cell Biol. 2009;29:2658&#x2013;2672. doi: 10.1128/MCB.01639-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.01639-08</ArticleId><ArticleId IdType="pmc">PMC2682049</ArticleId><ArticleId IdType="pubmed">19273602</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci. 2001;114(Pt13):2363&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">11559745</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem. 2001;70:81&#x2013;120. 10.1146/annurev.biochem.70.1.81.</Citation><ArticleIdList><ArticleId IdType="pubmed">11395403</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganner A, Pfeiffer Z-C, Wingendorf L, Kreis S, Klein M, Walz G, et al. The acetyltransferase p300 regulates NRF2 stability and localization. Biochem Biophys Res Commun. 2020;524:895&#x2013;902. doi: 10.1016/j.bbrc.2020.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.02.006</ArticleId><ArticleId IdType="pubmed">32057361</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzec JM, Christie JD, Reddy SP, Jedlicka AE, Vuong H, Lanken PN, et al. Functional polymorphisms in the transcription factor NRF2NRF2 in humans increase the risk of acute lung injury. FASEB J. 2007;21:2237&#x2013;46. in humans increase the risk of acute lung injury. FASEB J. 2007;21:2237&#x2013;2246. doi: 10.1096/fj.06-7759com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.06-7759com</ArticleId><ArticleId IdType="pubmed">17384144</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T, Shibata T, Takaya K, Shiraishi K, Kohno T, Kunitoh H, et al. Regulatory nexus of synthesis and degradation deciphers cellular Nrf2 expression levels. Mol Cell Biol. 2013;33:2402&#x2013;2412. doi: 10.1128/MCB.00065-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00065-13</ArticleId><ArticleId IdType="pmc">PMC3700104</ArticleId><ArticleId IdType="pubmed">23572560</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, Khor TO. Cheung K-L, Li W, Wu T-Y, Huang Y, et al. Nrf2 Expression Is Regulated by Epigenetic Mechanisms in Prostate Cancer of TRAMP Mice. Lau ATY, editor. PLoS ONE. 2010;5:e8579. doi: 10.1371/journal.pone.0008579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0008579</ArticleId><ArticleId IdType="pmc">PMC2799519</ArticleId><ArticleId IdType="pubmed">20062804</ArticleId></ArticleIdList></Reference><Reference><Citation>Sangokoya C, Telen MJ, Chi J-T. microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood. 2010;116:4338&#x2013;4348. doi: 10.1182/blood-2009-04-214817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-04-214817</ArticleId><ArticleId IdType="pmc">PMC2993631</ArticleId><ArticleId IdType="pubmed">20709907</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, Yao Y, Eades G, Zhang Y, Zhou Q. MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism. Breast Cancer Res Treat. 2011;129:983&#x2013;991. doi: 10.1007/s10549-011-1604-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-011-1604-1</ArticleId><ArticleId IdType="pmc">PMC3752913</ArticleId><ArticleId IdType="pubmed">21638050</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh B, Ronghe AM, Chatterjee A, Bhat NK, Bhat HK. MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis. Carcinogenesis. 2013;34:1165&#x2013;1172. doi: 10.1093/carcin/bgt026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/bgt026</ArticleId><ArticleId IdType="pmc">PMC3643421</ArticleId><ArticleId IdType="pubmed">23492819</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasimhan M, Patel D, Vedpathak D, Rathinam M, Henderson G, Mahimainathan L. Identification of novel microRNAs in Post-Transcriptional Control of Nrf2 Expression and Redox Homeostasis in Neuronal, SH-SY5Y Cells. Tsuji Y, editor. PLoS ONE. 2012;7:e51111. doi: 10.1371/journal.pone.0051111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0051111</ArticleId><ArticleId IdType="pmc">PMC3517581</ArticleId><ArticleId IdType="pubmed">23236440</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N, Zhang L, Lu Y, Zhang M, Zhang Z, Wang K, et al. Down-regulation of microRNA-142-5p attenuates oxygen-glucose deprivation and reoxygenation-induced neuron injury through up-regulating Nrf2/ARE signaling pathway. Biomed Pharmacother. 2017;89:1187&#x2013;1195. doi: 10.1016/j.biopha.2017.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2017.03.011</ArticleId><ArticleId IdType="pubmed">28320085</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, Muthusamy S, Liang R, Sarojini H, Wang E. Increased expression of miR-34a and miR-93 in rat liver during aging, and their impact on the expression of Mgst1 and Sirt1. Mech Ageing Dev. 2011;132:75&#x2013;85. doi: 10.1016/j.mad.2010.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2010.12.004</ArticleId><ArticleId IdType="pubmed">21216258</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetz C, Mollereau B. Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nat Rev Neurosci. 2014;15:233&#x2013;249. doi: 10.1038/nrn3689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3689</ArticleId><ArticleId IdType="pubmed">24619348</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Zhao F, Gao B, Tan C, Yagishita N, Nakajima T, et al. Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis. Genes Dev. 2014;28:708&#x2013;722. doi: 10.1101/gad.238246.114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.238246.114</ArticleId><ArticleId IdType="pmc">PMC4015486</ArticleId><ArticleId IdType="pubmed">24636985</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang HJ, Hong YB, Kim HJ, Bae I. CR6-interacting factor 1 (CRIF1) regulates NF-E2-related factor 2 (NRF2) protein stability by proteasome-mediated degradation. J Biol Chem. 2010;285:21258&#x2013;21268. doi: 10.1074/jbc.M109.084590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.084590</ArticleId><ArticleId IdType="pmc">PMC2898415</ArticleId><ArticleId IdType="pubmed">20427290</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba K, Morimoto H, Imaoka S. Seven in Absentia Homolog 2 (Siah2) protein is a regulator of NF-E2-related factor 2 (Nrf2) J Biol Chem. 2013;288:18393&#x2013;18405. doi: 10.1074/jbc.M112.438762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.438762</ArticleId><ArticleId IdType="pmc">PMC3689981</ArticleId><ArticleId IdType="pubmed">23645672</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Liu H, Zhou J-S, Cao J-F, Zhou X-B, Choi AMK, et al. Caveolin-1 inhibits expression of antioxidant enzymes through direct interaction with nuclear erythroid 2 p45-related factor-2 (Nrf2) J Biol Chem. 2012;287:20922&#x2013;20930. doi: 10.1074/jbc.M112.352336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.352336</ArticleId><ArticleId IdType="pmc">PMC3375516</ArticleId><ArticleId IdType="pubmed">22547061</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhakshinamoorthy S, Jain AK, Bloom DA, Jaiswal AK. Bach1 competes with Nrf2 leading to negative regulation of the antioxidant response element (ARE)-mediated NAD(P)H: quinone oxidoreductase 1 gene expression and induction in response to antioxidants. J Biol Chem. 2005;280:16891&#x2013;16900. doi: 10.1074/jbc.M500166200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M500166200</ArticleId><ArticleId IdType="pubmed">15734732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshino H, Kobayashi A, Yoshida M, Kudo N, Oyake T, Motohashi H, et al. Oxidative stress abolishes leptomycin B-sensitive nuclear export of transcription repressor Bach2 that counteracts activation of Maf recognition element. J Biol Chem. 2000;275:15370&#x2013;15376. doi: 10.1074/jbc.275.20.15370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.275.20.15370</ArticleId><ArticleId IdType="pubmed">10809773</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai Y, Gardu&#xf1;o L, Theodore M, Yang J, Arinze IJ. Acetylation-deacetylation of the transcription factor Nrf2 (Nuclear Factor Erythroid 2-related Factor 2) regulates its transcriptional activity and nucleocytoplasmic localization. J Biol Chem. 2011;286:7629&#x2013;7640. doi: 10.1074/jbc.M110.208173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.208173</ArticleId><ArticleId IdType="pmc">PMC3045017</ArticleId><ArticleId IdType="pubmed">21196497</ArticleId></ArticleIdList></Reference><Reference><Citation>Keum Y-S, Yu S, Chang PP-J, Yuan X, Kim J-H, Xu C, et al. Mechanism of action of sulforaphane: inhibition of p38 Mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element&#x2013;mediated heme oxygenase-1 in human hepatoma HepG2 cells. Cancer Res. 2006;66:8804&#x2013;8813. doi: 10.1158/0008-5472.CAN-05-3513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-05-3513</ArticleId><ArticleId IdType="pubmed">16951197</ArticleId></ArticleIdList></Reference><Reference><Citation>Niture SK, Khatri R, Jaiswal AK. Regulation of Nrf2&#x2014;an update. Free Radic Biol Med. 2014;66:36&#x2013;44. doi: 10.1016/j.freeradbiomed.2013.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.02.008</ArticleId><ArticleId IdType="pmc">PMC3773280</ArticleId><ArticleId IdType="pubmed">23434765</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain AK, Jaiswal AK. GSK-3&#x3b2; acts upstream of fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J Biol Chem. 2007;282:16502&#x2013;16510. doi: 10.1074/jbc.M611336200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M611336200</ArticleId><ArticleId IdType="pubmed">17403689</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;langer M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab. 2011;14:724&#x2013;738. doi: 10.1016/j.cmet.2011.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2011.08.016</ArticleId><ArticleId IdType="pubmed">22152301</ArticleId></ArticleIdList></Reference><Reference><Citation>McBean G. Cysteine, glutathione, and thiol redox balance in astrocytes. Antioxidants. 2017;6:62. doi: 10.3390/antiox6030062.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox6030062</ArticleId><ArticleId IdType="pmc">PMC5618090</ArticleId><ArticleId IdType="pubmed">28771170</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter MW, Beggs S. Sublime microglia: expanding roles for the guardians of the CNS. Cell. 2014;158:15&#x2013;24. doi: 10.1016/j.cell.2014.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.06.008</ArticleId><ArticleId IdType="pubmed">24995975</ArticleId></ArticleIdList></Reference><Reference><Citation>Nave K-A, Werner HB. Myelination of the nervous system: mechanisms and functions. Annu Rev Cell Dev Biol. 2014;30:503&#x2013;533. doi: 10.1146/annurev-cellbio-100913-013101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-100913-013101</ArticleId><ArticleId IdType="pubmed">25288117</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter PS, Hardingham GE. Adaptive regulation of the brain&#x2019;s antioxidant defences by neurons and astrocytes. Free Radic Biol Med. 2016;100:147&#x2013;152. doi: 10.1016/j.freeradbiomed.2016.06.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2016.06.027</ArticleId><ArticleId IdType="pmc">PMC5145800</ArticleId><ArticleId IdType="pubmed">27365123</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead RJ, Higginbottom A, Allen SP, Kirby J, Bennett E, Barber SC, et al. S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis. Free Radic Biol Med. 2013;61:438&#x2013;452. doi: 10.1016/j.freeradbiomed.2013.04.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.04.018</ArticleId><ArticleId IdType="pmc">PMC3684770</ArticleId><ArticleId IdType="pubmed">23608463</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarlette A, Krampfl K, Grothe C, Dengler R, Petri S. Nuclear erythroid 2YRelated Factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2008;67:8. doi: 10.1097/NEN.0b013e31818b4906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31818b4906</ArticleId><ArticleId IdType="pubmed">18957896</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanji K, Maruyama A, Odagiri S, Mori F, Itoh K, Kakita A, et al. Keap1 is localized in neuronal and glial cytoplasmic inclusions in various neurodegenerative diseases. J Neuropathol Exp Neurol. 2013;72:18&#x2013;28. doi: 10.1097/NEN.0b013e31827b5713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31827b5713</ArticleId><ArticleId IdType="pubmed">23242280</ArticleId></ArticleIdList></Reference><Reference><Citation>Goode A, Rea S, Sultana M, Shaw B, Searle MS, Layfield R. ALS-FTLD associated mutations of SQSTM1 impact on Keap1-Nrf2 signalling. Mol Cell Neurosci. 2016;76:52&#x2013;58. doi: 10.1016/j.mcn.2016.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2016.08.004</ArticleId><ArticleId IdType="pmc">PMC5062946</ArticleId><ArticleId IdType="pubmed">27554286</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakkar N, Kousari A, Kovalik T, Li Y, Bowser R. RBM45 modulates the antioxidant response in amyotrophic lateral sclerosis through interactions with KEAP1. Mol Cell Biol. 2015;35:2385&#x2013;2399. doi: 10.1128/MCB.00087-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00087-15</ArticleId><ArticleId IdType="pmc">PMC4475920</ArticleId><ArticleId IdType="pubmed">25939382</ArticleId></ArticleIdList></Reference><Reference><Citation>Copple IM, Lister A, Obeng AD, Kitteringham NR, Jenkins RE, Layfield R, et al. Physical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathway. J Biol Chem. 2010;285:16782&#x2013;16788. doi: 10.1074/jbc.M109.096545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.096545</ArticleId><ArticleId IdType="pmc">PMC2878012</ArticleId><ArticleId IdType="pubmed">20378532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau A, Wang X-J, Zhao F, Villeneuve NF, Wu T, Jiang T, et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol. 2010;30:3275&#x2013;3285. doi: 10.1128/MCB.00248-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00248-10</ArticleId><ArticleId IdType="pmc">PMC2897585</ArticleId><ArticleId IdType="pubmed">20421418</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Z, Lim J, Wang Q, Purtell K, Wu S, Palomo GM, et al. ALS-FTLD-linked mutations of SQSTM1/p62 disrupt selective autophagy and NFE2L2/NRF2 anti-oxidative stress pathway. Autophagy. 2020;16:917&#x2013;931. doi: 10.1080/15548627.2019.1644076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2019.1644076</ArticleId><ArticleId IdType="pmc">PMC7144840</ArticleId><ArticleId IdType="pubmed">31362587</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster A, Rea S. The role of sequestosome 1/p62 protein in amyotrophic lateral sclerosis and frontotemporal dementia pathogenesis. Neural Regen Res. 2020;15:2186. doi: 10.4103/1673-5374.284977.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.284977</ArticleId><ArticleId IdType="pmc">PMC7749485</ArticleId><ArticleId IdType="pubmed">32594029</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Lu Y, Qi F, Su Q, Wang L, You C, et al. Effect of the human SOD1-G93A gene on the Nrf2/ARE signaling pathway in NSC-34 cells. Mol Med Rep. 2014;9:2453&#x2013;2458. doi: 10.3892/mmr.2014.2087.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2014.2087</ArticleId><ArticleId IdType="pubmed">24682253</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood-Allum CA. Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen. Brain. 2006;129:1693&#x2013;1709. doi: 10.1093/brain/awl118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl118</ArticleId><ArticleId IdType="pubmed">16702190</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby J, Halligan E, Baptista MJ, Allen S, Heath PR, Holden H, et al. Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS. Brain. 2005;128:1686&#x2013;1706. doi: 10.1093/brain/awh503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh503</ArticleId><ArticleId IdType="pubmed">15872021</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan W, Guo Y, Jiang H, Yu X, Li C. MG132 enhances neurite outgrowth in neurons overexpressing mutant TAR DNA-binding protein-43 via increase of HO-1. Brain Res. 2011;1397:1&#x2013;9. doi: 10.1016/j.brainres.2011.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2011.05.006</ArticleId><ArticleId IdType="pubmed">21620381</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan W, Li X, Shi J, Guo Y, Li Z, Li C. Mutant TAR DNA-binding protein-43 induces oxidative injury in motor neuron-like cell. Neuroscience. 2010;169:1621&#x2013;1629. doi: 10.1016/j.neuroscience.2010.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2010.06.018</ArticleId><ArticleId IdType="pubmed">20600671</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M, Vargas MR, Robinson KM, Cassina P, Diaz-Amarilla PJ, Hagen TM, et al. Mitochondrial superoxide production and nuclear factor erythroid 2-Related Factor 2 activation in p75 neurotrophin receptor-induced motor neuron apoptosis. J Neurosci. 2007;27:7777&#x2013;7785. doi: 10.1523/JNEUROSCI.0823-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0823-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672870</ArticleId><ArticleId IdType="pubmed">17634371</ArticleId></ArticleIdList></Reference><Reference><Citation>Joilin G, Leigh PN, Newbury SF, Hafezparast M. An overview of MicroRNAs as biomarkers of ALS. Front Neurol. 2019;10:186. doi: 10.3389/fneur.2019.00186.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00186</ArticleId><ArticleId IdType="pmc">PMC6416171</ArticleId><ArticleId IdType="pubmed">30899244</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovanda A, Leonardis L, Zidar J, Koritnik B, Dolenc-Groselj L, Ristic Kovacic S, et al. Differential expression of microRNAs and other small RNAs in muscle tissue of patients with ALS and healthy age-matched controls. Sci Rep. 2018;8:5609. doi: 10.1038/s41598-018-23139-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-23139-2</ArticleId><ArticleId IdType="pmc">PMC5884852</ArticleId><ArticleId IdType="pubmed">29618798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricci C, Marzocchi C, Battistini S. MicroRNAs as biomarkers in amyotrophic lateral sclerosis. Cells. 2018;7:219. doi: 10.3390/cells7110219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells7110219</ArticleId><ArticleId IdType="pmc">PMC6262636</ArticleId><ArticleId IdType="pubmed">30463376</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzuti M, Filosa G, Melzi V, Calandriello L, Dioni L, Bollati V, et al. MicroRNA expression analysis identifies a subset of downregulated miRNAs in ALS motor neuron progenitors. Sci Rep. 2018;8:10105. doi: 10.1038/s41598-018-28366-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-28366-1</ArticleId><ArticleId IdType="pmc">PMC6031650</ArticleId><ArticleId IdType="pubmed">29973608</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller R, Wyles M, Heath PR, Kazoka M, Wollff H, Shaw PJ, et al. Small RNA sequencing of sporadic amyotrophic lateral sclerosis cerebrospinal fluid reveals differentially expressed miRNAs related to neural and glial activity. Front Neurosci. 2018;11:731. doi: 10.3389/fnins.2017.00731.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00731</ArticleId><ArticleId IdType="pmc">PMC5767269</ArticleId><ArticleId IdType="pubmed">29375285</ArticleId></ArticleIdList></Reference><Reference><Citation>Emde A, Eitan C, Liou L, Libby RT, Rivkin N, Magen I, et al. Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS. EMBO J. 2015;34:2633&#x2013;2651. doi: 10.15252/embj.201490493.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201490493</ArticleId><ArticleId IdType="pmc">PMC4641530</ArticleId><ArticleId IdType="pubmed">26330466</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft A, Resch J, Johnson D, Johnson J. Activation of the Nrf2&#x2013;ARE pathway in muscle and spinal cord during ALS-like pathology in mice expressing mutant SOD1. Exp Neurol. 2007;207:107&#x2013;117. doi: 10.1016/j.expneurol.2007.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2007.05.026</ArticleId><ArticleId IdType="pmc">PMC2062571</ArticleId><ArticleId IdType="pubmed">17631292</ArticleId></ArticleIdList></Reference><Reference><Citation>Mimoto T, Miyazaki K, Morimoto N, Kurata T, Satoh K, Ikeda Y, et al. Impaired antioxydative Keap1/Nrf2 system and the downstream stress protein responses in the motor neuron of ALS model mice. Brain Res. 2012;1446:109&#x2013;118. doi: 10.1016/j.brainres.2011.12.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2011.12.064</ArticleId><ArticleId IdType="pubmed">22353756</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci. 2008;28:13574&#x2013;13581. doi: 10.1523/JNEUROSCI.4099-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4099-08.2008</ArticleId><ArticleId IdType="pmc">PMC2866507</ArticleId><ArticleId IdType="pubmed">19074031</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Pehar M, Cassina P, Mart&#xed;nez-Palma L, Thompson JA, Beckman JS, et al. Fibroblast Growth Factor-1 Induces Heme Oxygenase-1 via Nuclear Factor Erythroid 2-related Factor 2 (Nrf2) in Spinal Cord Astrocytes: CONSEQUENCES FOR MOTOR NEURON SURVIVAL. J Biol Chem. 2005;280:25571&#x2013;25579. doi: 10.1074/jbc.M501920200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M501920200</ArticleId><ArticleId IdType="pubmed">15870071</ArticleId></ArticleIdList></Reference><Reference><Citation>Neymotin A, Calingasan NY, Wille E, Naseri N, Petri S, Damiano M, et al. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med. 2011;51:88&#x2013;96. doi: 10.1016/j.freeradbiomed.2011.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2011.03.027</ArticleId><ArticleId IdType="pmc">PMC3109235</ArticleId><ArticleId IdType="pubmed">21457778</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollari E, Goldsteins G, Bart G, Koistinaho J, Giniatullin R. The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis. Front Cell Neurosci. 2014;8:131. 10.3389/fncel.2014.00131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4026683</ArticleId><ArticleId IdType="pubmed">24860432</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Zhang Y, Wen D, Duan W, An T, Shi P, et al. The modest impact of transcription factor Nrf2 on the course of disease in an ALS animal model. Lab Invest. 2013;93:825&#x2013;833. doi: 10.1038/labinvest.2013.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/labinvest.2013.73</ArticleId><ArticleId IdType="pubmed">23711824</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas MR, Burton NC, Gan L, Johnson DA, Sch&#xe4;fer M, Werner S, et al. Absence of Nrf2 or Its Selective Overexpression in Neurons and Muscle Does Not Affect Survival in ALS-Linked Mutant hSOD1 Mouse Models. Borchelt DR, editor. PLoS ONE. 2013;8:e56625. doi: 10.1371/journal.pone.0056625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0056625</ArticleId><ArticleId IdType="pmc">PMC3572065</ArticleId><ArticleId IdType="pubmed">23418589</ArticleId></ArticleIdList></Reference><Reference><Citation>Vomund S, Sch&#xe4;fer A, Parnham M, Br&#xfc;ne B, von Knethen A. Nrf2, the master regulator of anti-oxidative responses. Int J Mol Sci. 2017;18:2772. doi: 10.3390/ijms18122772.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18122772</ArticleId><ArticleId IdType="pmc">PMC5751370</ArticleId><ArticleId IdType="pubmed">29261130</ArticleId></ArticleIdList></Reference><Reference><Citation>Hur W, Gray NS. Small molecule modulators of antioxidant response pathway. Curr Opin Chem Biol. 2011;15:162&#x2013;173. doi: 10.1016/j.cbpa.2010.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbpa.2010.12.009</ArticleId><ArticleId IdType="pubmed">21195017</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T, McKercher SR, Lipton SA. Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs. Free Radic Biol Med. 2013;65:645&#x2013;657. doi: 10.1016/j.freeradbiomed.2013.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.07.022</ArticleId><ArticleId IdType="pmc">PMC3859717</ArticleId><ArticleId IdType="pubmed">23892355</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, Gribble GW. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod. 2011;74:537&#x2013;545. doi: 10.1021/np100826q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/np100826q</ArticleId><ArticleId IdType="pmc">PMC3064114</ArticleId><ArticleId IdType="pubmed">21309592</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci. 2005;102:4584&#x2013;4589. doi: 10.1073/pnas.0500815102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0500815102</ArticleId><ArticleId IdType="pmc">PMC555528</ArticleId><ArticleId IdType="pubmed">15767573</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabbani PS, Ellison T, Waqas B, Sultan D, Abdou S, David JA, et al. Targeted Nrf2 activation therapy with RTA 408 enhances regenerative capacity of diabetic wounds. Diabetes Res Clin Pract. 2018;139:11&#x2013;23. doi: 10.1016/j.diabres.2018.02.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2018.02.021</ArticleId><ArticleId IdType="pubmed">29476889</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch DR, Farmer J, Hauser L, Blair IA, Wang QQ, Mesaros C, et al. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. Ann Clin Transl Neurol. 2019;6:15&#x2013;26. doi: 10.1002/acn3.660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.660</ArticleId><ArticleId IdType="pmc">PMC6331199</ArticleId><ArticleId IdType="pubmed">30656180</ArticleId></ArticleIdList></Reference><Reference><Citation>Paupe V, Dassa EP, Goncalves S, Auch&#xe8;re F, L&#xf6;nn M, Holmgren A, et al. Impaired Nuclear Nrf2 Translocation Undermines the Oxidative Stress Response in Friedreich Ataxia. Andreu AL, editor. PLoS ONE. 2009;4:e4253. doi: 10.1371/journal.pone.0004253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0004253</ArticleId><ArticleId IdType="pmc">PMC2617762</ArticleId><ArticleId IdType="pubmed">19158945</ArticleId></ArticleIdList></Reference><Reference><Citation>Linker RA, Lee D-H, Ryan S, van Dam AM, Conrad R, Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134:678&#x2013;692. doi: 10.1093/brain/awq386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq386</ArticleId><ArticleId IdType="pubmed">21354971</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrowietz C. Altmeyer, THE PARTICIPANTS IN THE GERMAN MULTICENTRE STUDY. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. Br J Dermatol. 1998;138:456&#x2013;460. doi: 10.1046/j.1365-2133.1998.02124.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2133.1998.02124.x</ArticleId><ArticleId IdType="pubmed">9580799</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez &#xd3;, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, et al. Efficacy and safety of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis in prior interferon users: an integrated analysis of DEFINE and CONFIRM. Clin Ther. 2017;39:1671&#x2013;1679. doi: 10.1016/j.clinthera.2017.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2017.06.012</ArticleId><ArticleId IdType="pubmed">28751099</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox RJ, Gold R, Phillips JT, Okwuokenye M, Zhang A, Marantz JL. Efficacy and tolerability of delayed-release dimethyl fumarate in Black, Hispanic, and Asian patients with relapsing-remitting multiple sclerosis: Post Hoc integrated analysis of DEFINE and CONFIRM. Neurol Ther. 2017;6:175&#x2013;187. doi: 10.1007/s40120-017-0077-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40120-017-0077-5</ArticleId><ArticleId IdType="pmc">PMC5700899</ArticleId><ArticleId IdType="pubmed">28770420</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly JF, Ya&#xf1;ez G, Bista P, Picarella D, Lee D, Vu C, et al. CAT-4001 improves mitochondrial function in a Friedreich&#x2019;s ataxia model. Italy: Proc 2nd Int Ataxia Res Conf Pisa; 2017. pp. 27&#x2013;30.</Citation></Reference><Reference><Citation>Voloboueva LA, Killilea DW, Atamna H, Ames BN. N-tert-butyl hydroxylamine, a mitochondrial antioxidant, protects human retinal pigment epithelial cells from iron overload: relevance to macular degeneration. FASEB J. Wiley Online Library. 2007;21:4077&#x2013;4086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597693</ArticleId><ArticleId IdType="pubmed">17656467</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman BA, O&#x2019;Donnell VB, Schopfer FJ. The discovery of nitro-fatty acids as products of metabolic and inflammatory reactions and mediators of adaptive cell signaling. Nitric Oxide. 2018;77:106&#x2013;111. doi: 10.1016/j.niox.2018.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.niox.2018.05.002</ArticleId><ArticleId IdType="pmc">PMC5983901</ArticleId><ArticleId IdType="pubmed">29742447</ArticleId></ArticleIdList></Reference><Reference><Citation>Kansanen E, Bonacci G, Schopfer FJ, Kuosmanen SM, Tong KI, Leinonen H, et al. Electrophilic nitro-fatty acids activate NRF2 by a KEAP1 cysteine 151-independent mechanism. J Biol Chem. 2011;286:14019&#x2013;14027. doi: 10.1074/jbc.M110.190710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.190710</ArticleId><ArticleId IdType="pmc">PMC3077602</ArticleId><ArticleId IdType="pubmed">21357422</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Duarte J, Dapueto R, Galliussi G, Turell L, Kamaid A, Khoo NKH, et al. Electrophilic nitroalkene-tocopherol derivatives: synthesis, physicochemical characterization and evaluation of anti-inflammatory signaling responses. Sci Rep. 2018;8:12784. doi: 10.1038/s41598-018-31218-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-31218-7</ArticleId><ArticleId IdType="pmc">PMC6109136</ArticleId><ArticleId IdType="pubmed">30143727</ArticleId></ArticleIdList></Reference><Reference><Citation>Cores &#xc1;, Piquero M, Villacampa M, Le&#xf3;n R, Men&#xe9;ndez JC. NRF2 regulation processes as a source of potential drug targets against neurodegenerative diseases. Biomolecules. 2020;10:904. doi: 10.3390/biom10060904.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10060904</ArticleId><ArticleId IdType="pmc">PMC7356958</ArticleId><ArticleId IdType="pubmed">32545924</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci. 1992;89:2399&#x2013;2403. doi: 10.1073/pnas.89.6.2399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.6.2399</ArticleId><ArticleId IdType="pmc">PMC48665</ArticleId><ArticleId IdType="pubmed">1549603</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh K, Connors SL, Macklin EA, Smith KD, Fahey JW, Talalay P, et al. Sulforaphane treatment of autism spectrum disorder (ASD) Proc Natl Acad Sci. 2014;111:15550&#x2013;15555. doi: 10.1073/pnas.1416940111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1416940111</ArticleId><ArticleId IdType="pmc">PMC4217462</ArticleId><ArticleId IdType="pubmed">25313065</ArticleId></ArticleIdList></Reference><Reference><Citation>Robledinos-Ant&#xf3;n N, Fern&#xe1;ndez-Gin&#xe9;s R, Manda G, Cuadrado A. Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxid Med Cell Longev. 2019;2019:9372182. 10.1155/2019/9372182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6664516</ArticleId><ArticleId IdType="pubmed">31396308</ArticleId></ArticleIdList></Reference><Reference><Citation>Egea J, Buendia I, Parada E, Navarro E, Rada P, Cuadrado A, et al. Melatonin-sulforaphane hybrid ITH12674 induces neuroprotection in oxidative stress conditions by a &#x2018;drug-prodrug&#x2019; mechanism of action: A designed dual-acting melatonin-sulforaphane hybrid. Br J Pharmacol. 2015;172:1807&#x2013;1821. doi: 10.1111/bph.13025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13025</ArticleId><ArticleId IdType="pmc">PMC4376458</ArticleId><ArticleId IdType="pubmed">25425158</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell SJ, Campone M, Cort&#xe9;s J, Duhoux FP, Ross S, Morris T, et al. Final results of the STEM trial: SFX-01 in the treatment and evaluation of ER+ Her2-metastatic breast cancer (mBC) Ann Oncol. Elsevier. 2019;30:v122. doi: 10.1093/annonc/mdz242.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdz242.036</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolnourian AH, Franklin S, Galea I, Bulters DO. Study protocol for SFX-01 after subarachnoid haemorrhage (SAS): a multicentre randomised double-blinded, placebo controlled trial. BMJ Open. 2020;10:e028514. doi: 10.1136/bmjopen-2018-028514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-028514</ArticleId><ArticleId IdType="pmc">PMC7170552</ArticleId><ArticleId IdType="pubmed">32217557</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirotsu Y, Katsuoka F, Itoh K, Yamamoto M. Nrf2 degron-fused reporter system: a new tool for specific evaluation of Nrf2 inducers: Nrf2 degron-fused reporter system. Genes Cells. 2011;16:406&#x2013;415. doi: 10.1111/j.1365-2443.2011.01496.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2443.2011.01496.x</ArticleId><ArticleId IdType="pubmed">21392184</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi C, Kawaji A, Tsuda N, Hayashi M, Saito R, Yagishita Y, et al. The novel Nrf2 inducer TFM-735 ameliorates experimental autoimmune encephalomyelitis in mice. Eur J Pharmacol. 2017;802:76&#x2013;84. doi: 10.1016/j.ejphar.2017.02.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2017.02.044</ArticleId><ArticleId IdType="pubmed">28246026</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies TG, Wixted WE, Coyle JE, Griffiths-Jones C, Hearn K, McMenamin R, et al. Monoacidic inhibitors of the Kelch-like ECH-Associated Protein 1: nuclear factor Erythroid 2-related factor 2 (KEAP1:NRF2) protein&#x2013;protein interaction with high cell potency identified by fragment-based discovery. J Med Chem. 2016;59:3991&#x2013;4006. doi: 10.1021/acs.jmedchem.6b00228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.6b00228</ArticleId><ArticleId IdType="pubmed">27031670</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallesen JS, Tran KT, Bach A. Non-covalent small-molecule Kelch-like ECH-associated protein 1&#x2013;nuclear factor Erythroid 2-related Factor 2 (Keap1&#x2013;Nrf2) inhibitors and their potential for targeting central nervous system diseases. J Med Chem. 2018;61:8088&#x2013;8103. doi: 10.1021/acs.jmedchem.8b00358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.8b00358</ArticleId><ArticleId IdType="pubmed">29750408</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmoll D, Engel CK, Glombik H. The Keap1&#x2013;Nrf2 protein&#x2013;protein interaction: a suitable target for small molecules. Drug Discov Today Technol. 2017;24:11&#x2013;17. doi: 10.1016/j.ddtec.2017.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ddtec.2017.10.001</ArticleId><ArticleId IdType="pubmed">29233294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Redell JB, Moore AN, Dash PK. A novel strategy to activate cytoprotective genes in the injured brain. Biochem Biophys Res Commun. 2011;407:501&#x2013;506. doi: 10.1016/j.bbrc.2011.03.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2011.03.046</ArticleId><ArticleId IdType="pmc">PMC4264351</ArticleId><ArticleId IdType="pubmed">21414291</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu J, Zhang X, Zhu Y, Dai Y, Li N, Yang F, et al. Cell-permeable peptide targeting the Nrf2-Keap1 interaction: a potential novel therapy for global cerebral ischemia. J Neurosci Off J Soc Neurosci. 2015;35:14727&#x2013;14739. doi: 10.1523/JNEUROSCI.1304-15.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1304-15.2015</ArticleId><ArticleId IdType="pmc">PMC4635127</ArticleId><ArticleId IdType="pubmed">26538645</ArticleId></ArticleIdList></Reference><Reference><Citation>Attucks OC, Jasmer KJ, Hannink M, Kassis J, Zhong Z, Gupta S, et al. Induction of Heme Oxygenase I (HMOX1) by HPP-4382: A Novel Modulator of Bach1 Activity. Yang C-M, editor. PLoS ONE. 2014;9:e101044. doi: 10.1371/journal.pone.0101044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0101044</ArticleId><ArticleId IdType="pmc">PMC4096395</ArticleId><ArticleId IdType="pubmed">25019514</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S-K, Kassis J, Attucks O, Zhong Z, Freeman J, Gupta S, et al. The novel Bach1 inhibitor HPP971 uniquely activates Nrf2 and reduces disease severity in a mouse model of experimental autoimmune encephalomyelitis. ACTRIMS-ECTRIMS Meet. 2014.</Citation></Reference><Reference><Citation>Luo J. Glycogen synthase kinase 3&#x3b2; (GSK3&#x3b2;) in tumorigenesis and cancer chemotherapy. Cancer Lett. 2009;273:194&#x2013;200. doi: 10.1016/j.canlet.2008.05.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2008.05.045</ArticleId><ArticleId IdType="pmc">PMC4978950</ArticleId><ArticleId IdType="pubmed">18606491</ArticleId></ArticleIdList></Reference><Reference><Citation>Lal H, Ahmad F, Woodgett J, Force T. The GSK-3 family as therapeutic target for myocardial diseases. Circ Res. 2015;116:138&#x2013;149. doi: 10.1161/CIRCRESAHA.116.303613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.116.303613</ArticleId><ArticleId IdType="pmc">PMC4283216</ArticleId><ArticleId IdType="pubmed">25552693</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer&#x2019;s disease: GSK3 and Alzheimer&#x2019;s disease. J Neurochem. 2008;104:1433&#x2013;1439. doi: 10.1111/j.1471-4159.2007.05194.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.05194.x</ArticleId><ArticleId IdType="pmc">PMC3073119</ArticleId><ArticleId IdType="pubmed">18088381</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizunoe Y, Kobayashi M, Sudo Y, Watanabe S, Yasukawa H, Natori D, et al. Trehalose protects against oxidative stress by regulating the Keap1&#x2013;Nrf2 and autophagy pathways. Redox Biol. 2018;15:115&#x2013;124. doi: 10.1016/j.redox.2017.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2017.09.007</ArticleId><ArticleId IdType="pmc">PMC5730428</ArticleId><ArticleId IdType="pubmed">29241092</ArticleId></ArticleIdList></Reference><Reference><Citation>Calap-Quintana P, Soriano S, Llorens JV, Al-Ramahi I, Botas J, Molt&#xf3; MD, et al. TORC1 Inhibition by Rapamycin Promotes Antioxidant Defences in a Drosophila Model of Friedreich&#x2019;s Ataxia. Palau F, editor. PLOS ONE. 2015;10:e0132376. doi: 10.1371/journal.pone.0132376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0132376</ArticleId><ArticleId IdType="pmc">PMC4497667</ArticleId><ArticleId IdType="pubmed">26158631</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Z-W, Kelly R, Winans T, Marchena I, Shadakshari A, Yu J, et al. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. The Lancet. 2018;391:1186&#x2013;1196. doi: 10.1016/S0140-6736(18)30485-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)30485-9</ArticleId><ArticleId IdType="pmc">PMC5891154</ArticleId><ArticleId IdType="pubmed">29551338</ArticleId></ArticleIdList></Reference><Reference><Citation>Piemonti L, Maffi P, Monti L, Lampasona V, Perseghin G, Magistretti P, et al. Beta cell function during rapamycin monotherapy in long-term type 1 diabetes. Diabetologia. 2011;54:433&#x2013;439. doi: 10.1007/s00125-010-1959-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-010-1959-6</ArticleId><ArticleId IdType="pubmed">21046356</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, D&#x2019;Amico R, Zucchi E, Gessani A, Fini N, Fasano A, et al. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial) Medicine (Baltimore) 2018;97:e11119. doi: 10.1097/MD.0000000000011119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000011119</ArticleId><ArticleId IdType="pmc">PMC6024184</ArticleId><ArticleId IdType="pubmed">29901635</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Ryder J, Mekhael L, Rd H, Mathers S, Needham M, et al. Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant) Medicine (Baltimore) 2020;99:e18904. doi: 10.1097/MD.0000000000018904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000018904</ArticleId><ArticleId IdType="pmc">PMC7015658</ArticleId><ArticleId IdType="pubmed">32028398</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney MD, Sagare AP, Zlokovic BV. Blood&#x2013;brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14:133&#x2013;150. doi: 10.1038/nrneurol.2017.188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.188</ArticleId><ArticleId IdType="pmc">PMC5829048</ArticleId><ArticleId IdType="pubmed">29377008</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilhardt F, Haslund-Vinding J, Jaquet V, McBean G. Microglia antioxidant systems and redox signalling. Br J Pharmacol. 2017;174:1719&#x2013;1732. doi: 10.1111/bph.13426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13426</ArticleId><ArticleId IdType="pmc">PMC5446583</ArticleId><ArticleId IdType="pubmed">26754582</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou T, Ahmad TK, Gozda K, Truong J, Kong J, Namaka M. Implications of white matter damage in amyotrophic lateral sclerosis (Review) Mol Med Rep. 2017;16:4379&#x2013;4392. doi: 10.3892/mmr.2017.7186.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2017.7186</ArticleId><ArticleId IdType="pmc">PMC5646997</ArticleId><ArticleId IdType="pubmed">28791401</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n-Montalvo A, Villalba JM, Navas P, de Cabo R. NRF2, cancer and calorie restriction. Oncogene. 2011;30:505&#x2013;520. doi: 10.1038/onc.2010.492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2010.492</ArticleId><ArticleId IdType="pmc">PMC4684645</ArticleId><ArticleId IdType="pubmed">21057541</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer. 2012;12:564&#x2013;571. doi: 10.1038/nrc3278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3278</ArticleId><ArticleId IdType="pmc">PMC3836441</ArticleId><ArticleId IdType="pubmed">22810811</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson M, de la Vega MR, Cholanians AB, Schmidlin CJ, Chapman E, Zhang DD. Modulating NRF2 in disease: timing is everything. Annu Rev Pharmacol Toxicol. 2019;59:555&#x2013;575. doi: 10.1146/annurev-pharmtox-010818-021856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-010818-021856</ArticleId><ArticleId IdType="pmc">PMC6538038</ArticleId><ArticleId IdType="pubmed">30256716</ArticleId></ArticleIdList></Reference><Reference><Citation>Menegon S, Columbano A, Giordano S. The dual roles of NRF2 in cancer. Trends Mol Med. 2016;22:578&#x2013;593. doi: 10.1016/j.molmed.2016.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2016.05.002</ArticleId><ArticleId IdType="pubmed">27263465</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006;3:e420. doi: 10.1371/journal.pmed.0030420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0030420</ArticleId><ArticleId IdType="pmc">PMC1584412</ArticleId><ArticleId IdType="pubmed">17020408</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppke P, Weissbach S, Church JA, Schnur R, Krusen M, Dreha-Kulaczewski S, et al. Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem disorder. Nat Commun. 2017;8:818. doi: 10.1038/s41467-017-00932-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00932-7</ArticleId><ArticleId IdType="pmc">PMC5635015</ArticleId><ArticleId IdType="pubmed">29018201</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, Lu H, Bai Y. Nrf2 in cancers: A double-edged sword. Cancer Med. 2019;8:2252&#x2013;2267. doi: 10.1002/cam4.2101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.2101</ArticleId><ArticleId IdType="pmc">PMC6536957</ArticleId><ArticleId IdType="pubmed">30929309</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Tortelli R, Rizzo G, Marin B, Preux PM, Malaspina A. Amyotrophic Lateral Sclerosis: An Aging-Related Disease. Curr Geriatr Rep. 2015;4:142&#x2013;153. doi: 10.1007/s13670-015-0127-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13670-015-0127-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408:239&#x2013;247. doi: 10.1038/35041687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35041687</ArticleId><ArticleId IdType="pubmed">11089981</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandya VA, Patani R. Decoding the relationship between ageing and amyotrophic lateral sclerosis: a cellular perspective. Brain. 2020;143:1057&#x2013;1072. doi: 10.1093/brain/awz360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz360</ArticleId><ArticleId IdType="pmc">PMC7174045</ArticleId><ArticleId IdType="pubmed">31851317</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Davies KJA, Forman HJ. Oxidative stress response and Nrf2 signaling in aging. Free Radic Biol Med. 2015;88:314&#x2013;336. doi: 10.1016/j.freeradbiomed.2015.05.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.05.036</ArticleId><ArticleId IdType="pmc">PMC4628850</ArticleId><ArticleId IdType="pubmed">26066302</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss P, Siems W. Clinical oxidation parameters of aging. Free Radic Res. 2006;40:1339&#x2013;1349. doi: 10.1080/10715760600953859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10715760600953859</ArticleId><ArticleId IdType="pubmed">17090423</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>